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The Genus Moraxella
The Moraxella genus currently contains at least 14 different species, including
M. catarrhalis, M. bovis, M. lacunata, M. osloensis, M. nonliquefaciens, M. atlantae, M. lincolnii,
M. ovis, M. caviae, M. canis, M. equi, M. cuniculi, M. caprae and M. boevreii, which colonize
both humans and animals. Four of these species, namely M. catarrhalis, M. caviae, M. ovis,
and M. cuniculi, may be separated into a separate subgenus, the Branhamella subgenus (i.e.
M. (B.) catarrhalis, Moraxella (Branhamella) catarrhalis).  Using this system, the remaining
species are included in the subgenus Moraxella (i.e. M. (M.) lacunata, Moraxella (Moraxella)
lacunata). This division is based largely on morphological characteristics, in that sub-
genus Moraxella (Branhamella) spp. tend to exhibit coccoid morphology, whilst subgenus
Moraxella (Moraxella) spp exhibit rod-like morphology. However, many publications
tend to omit the (B). / (M). or (Branhamella) / (Moraxella) subgenus designation. Also,
the Moraxella genus itself is under constant revision, with recent taxonomic re-
structuring placing the bacterial species formerly known as Moraxella phenylpyruvica in the
genus Psychrobacter as Psychrobacter phenylpyruvica and Moraxella urethralis in the Oligella
genus as Oligella urethralis. Common characteristics of the Moraxella genus include: a lack
of colony pigmentation; Gram-negative staining coccoid/bacillus morphology with a
tendency to resist decolorisation; positive with oxidase reagent and tetra-/dimethyl-p-
phenylenediamine; and a GC content of between 40 and 47.5 mol%. Optimum growth
conditions are achieved on blood agar plates under aerobic conditions at a temperature
of approximately 33-37oC. In general, distinguishing between the different Moraxella
species tends to be difficult, not least because of the asaccharolytic nature of the genus,
though some publications have indicated that 16S rRNA sequence polymorphisms may
be a useful adjunct to biochemical testing (12, 15, 19). The majority of Moraxella spp. are
susceptible to penicillin-derived antibiotics, including cephalosporins, tetracyclines,
quinolones and aminoglycosides. This contrasts with M. catarrhalis, where an alarming
increase in the number of penicillin resistant isolates has been observed in the last 30
years (now approximating 90-95% of all isolations). This distinction in antibiotic
sensitivity is most probably related to the fact that M. catarrhalis produces beta-
lactamases enzymes, a phenomenon apparently rare in other Moraxella spp. (though at
least one publication has indicated otherwise with respect to M. nonliquefaciens (11)).
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Moraxella catarrhalis
The bacterial species known as Moraxella catarrhalis (previously referred to as
Micrococcus catarrhalis, Neisseria catarrhalis, Branhamella catarrhalis and Moraxella (Branhamella)
catarrhalis) was originally thought to be a common human commensal bacterium with
little pathogenic potential, a characteristic currently shared by most other species within
the Moraxella genus. However, growing evidence collected over the last 30 years has
proven the clinical relevance of this organism in facilitating disease in both adults and
children. The main question now remaining is the mechanism(s) by which the organism
switches from being a harmless commensal to a facilitator of pathogenic disease.
Taxonomy
             Moraxella catarrhalis has undergone several name changes since its first discovery
in 1896 (13). Originally entitled Micrococcus catarrhalis, the organism became more
familiar as Neisseria catarrhalis in the 1950's, largely due to its Gram-negative,
diplococcoid morphology and rapid oxidase positive reaction (characteristics associated
with Neisseria species). In 1963 however, Berger showed that this genus may actually
contain two distinct species (Neisseria cinerea and Neisseria catarrhalis), which could be
separated by their biochemical ability to reduce nitrate and nitrite and to utilise
tributyrin (3). With the introduction of DNA technology, further phylogenetic studies
indicated a lack of chromosomal DNA homology, between the ''true'' Neisseria spp. and
N. catarrhalis, so much so, that in 1970 the species was renamed Branhamella catarrhalis
and relocated to the new genus of Branhamella to honour the famous microbiologist
Sarah E. Branham who had previously conducted research on Neisseria (8). Fourteen
years later, Bovre suggested that B. catarrhalis be renamed Moraxella (Branhamella)
catarrhalis and be re-assigned to the genus Moraxella, not least because of the distinct
physiological and genetic relatedness between Branhamella catarrhalis, and members of
the Moraxella genus (5). In 1991, Catlin (6) suggested the formation of a new family (the
Branhamaceae), which would accommodate both Branhamella and Moraxella genera and
take into account the differences in morphology (cocci versus rods) and pathogenicity
(important mucosal pathogens versus rare causes of disease). However, this suggestion
has not been adopted by taxonomists, not least because 16S ribosomal RNA sequence
analysis and genetic hybridisation studies tend to favour the current classification of M.
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catarrhalis (12, 19). Currently, the Moraxella genus contains both rod-shaped (genus
Moraxella, subgenus Moraxella) and coccoid (genus Moraxella, subgenus Branhamella)
bacteria exhibiting similar genetic relatedness, though taxonomic revision of the genus
is a continuing process.  Indeed, there is growing evidence to suggest that the current
M. catarrhalis genus may actually represent two different sub-species or even distinct
species per se (4, 22).
Isolation and Identification
Optimum growth conditions for M. catarrhalis include a temperature of 35-37oC
in an atmosphere containing 3%-7% CO2, though the organism is also capable of
growing at a larger range of temperatures (20-42oC) and in ambient air. Pure cultures of
M. catarrhalis may be grown on standard laboratory media including Mueller Hinton
agar, Columbia blood agar, and brain heart infusion or tryptic soy digest broths, though
the addition of supplements e.g. boiled blood plus vitamin / amino acid enrichment
(chocolate agar) may result in an enhancement of growth (9). A defined medium for M.
catarrhalis culture was described by Juni et al in 1986 (17). Unfortunately however, the
growth of M. catarrhalis from clinical specimens may be somewhat complicated by the
presence of the normal bacterial flora, and in particular the presence of non-pathogenic
Neisseria. For this reason, selective agars may best be used for the isolation of M.
catarrhalis from clinical specimens such as sputum etc. Several types of selective media
have been described for M. catarrhalis with a common feature being the inclusion of
trimethoprim, vancomycin and an antifungal agent, with the further addition of
acetazolamide (a synthetic sulphonamide) having been reported to enhance recovery
(21). Of interest, it has been reported that M. catarrhalis isolated on modified New York
City (MNYC) medium containing antibiotics selective for pathogenic Neisseria, may
possess a greater virulence potential than isolates which do not grow on this medium
(10). M. catarrhalis does not grow on Modified Thayer-Martin (MTM) medium. For
long-term storage (several years) at -80oC, STGG (skimmed milk, tryptone, glucose,
glycerol) medium has been reported to yield encouraging results (18).
M. catarrhalis colonies tend to be large, grey or non-pigmented, smooth, opaque
and convex in nature and may be readily pushed intact over the surface of agar using a
sterile loop. In a typical Gram film, the organism appears as a Gram-negative
diplococcus with flattened sides, though physical appearance by itself is not enough to
separate the species from related contaminating Neisseria spp. The identification of M.
Chapter 1                                                                                                                       General Introduction
13
catarrhalis to the species level involves biochemical testing with the production of
oxidase, expression of a DNAse, lack of acid production from glucose, sucrose, lactose,
maltose and fructose, reduction of nitrate and nitrite, and the hydrolysis of tributyrin
being important, though none of these tests are 100% specific or sensitive by
themselves (7). The use of DNA technology, and in particular PCR, has allowed the
direct detection of M. catarrhalis from clinical isolates (middle ear effusions,
nasopharyngeal secretions etc) without the prior need for culture, with the validity of
PCR detection having been proved in animal models (1, 20). Indeed, results show a
superior sensitivity for PCR (down to six or seven genome equivalents over more
traditional culturing methods (20)). Recent research has also shown that PCR may be
used to follow quantitative changes in M. catarrhalis numbers in nasopharyngeal
secretions in “real-time”, perhaps offering a sensitive and reliable means of following
disease progress and/or treatment regimens in the future (14). However, perhaps the
most useful aspect of PCR with regard to clinical diagnosis, is the ability of multiplex
PCR protocols to detect several pathogens in a single reaction mix, including the
bacterial pathogens M. catarrhalis, Haemophilus influenzae and Streptococcus pneumonia. Such
multiplex PCRs have already been validated in animal models (2) and have been shown
to be a reliable diagnostic tool allowing screening of middle ear effusions for several
pathogens (including Alloiococcus otitidis) within a single reaction tube and within a single
working day (16).
AIMS AND OUTLINE OF THE THESIS
The aim of this thesis was to help define the contribution of
Moraxella catarrhalis genetic diversity on the ability of the bacterium to colonise and
cause infection in the human host, as well as to investigate novel genes/mechanisms
associated with isolates exhibiting the complement resistance phenotype.
In this respect, Chapters 1 and 2 provide a detailed description of our current
knowledge regarding the Moraxella genus in general and the Moraxella catarrhalis species
in particular. The subsequent nine chapters are then divided into two main themes,
relating to M. catarrhalis genotypes/genotypic changes (Chapters 3 – 6), and the
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identification and characterisation of novel genes/mechanisms associated with the
complement phenotype within this species (Chapters 7 – 10).
Chapter 3 investigates the genetic diversity of M. catarrhalis within a population
of hospitalised children, and the effect of genotypic changes on concomitant disease.
Chapter 4 explores possible changes in M. catarrhalis genotypes and complement
phenotype after vaccination with a Streptococcus pneumoniae vaccine (an organism that
shares the same biological niche as M. catarrhalis). The following chapter (Chapter 5)
represents the most extensive investigation into any group of M. catarrhalis isolates to
date, using intensive whole-cell genotyping and protein profiling techniques to study
complement phenotype-specific markers within this species. Such markers could be
useful in developing screening techniques to distinguish between lineages of M.
catarrhalis exhibiting differential virulence traits. Chapter 6 studies genotypic and
complement phenotype variation in M. catarrhalis with respect to otitis media prone and
otitis media non-prone children. In the same chapter, low frequency intra-genomic
variation in the UspA1 and UspA2 outer membrane proteins (previously associated
with conferring complement resistance) are described.
With respect to genes/mechanisms associated with the complement
phenotype, Chapter 7 details research undertaken into the identification and
characterisation of a novel major outer membrane protein of M. catarrhalis (OMP J) that
exists in two major forms. Moreover, these forms are significantly associated with
particular genetic lineages as well as the complement phenotype. The effect of knocking
out the ompJ2 gene on the pulmonary clearance of M. catarrhalis in a mouse model of
infection is also investigated. In Chapter 8, studies are performed into the role of OMP
J in the immune response to M. catarrhalis using sera collected from children suffering
from acute otitis media (AOM). The effect of passive immunisation, using anti-OMP J
antibodies, on the clearance of M. catarrhalis bacteria from the lungs of mice is also
described. Chapter 9 investigates the role of the mannose-binding lectin (MBL)
pathway of complement activation on M. catarrhalis isolates cultured from children who
suffered from recurrent acute otitis media episodes. This chapter provides information
regarding the role of the MBL pathway on M. catarrhalis survival upon exposure to
human serum. In Chapter 10, a search is performed for novel M. catarrhalis plasmids
which may be useful as cloning and expression vectors for putative M. catarrhalis
virulence genes (including complement resistance-associated genes). The chapter details
the identification, isolation and characterisation of a small 3.5kb plasmid named
pEMCJH04.
Chapter 1                                                                                                                       General Introduction
15
Finally, Chapter 11 gives a summary of the research presented within this
thesis and discusses the findings with respect to M. catarrhalis genotypic lineage and
complement resistance phenotype.
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ASSOCIATED DISEASES
Although once being considered a harmless commensal, it is now recognised
that Moraxella catarrhalis is an important pathogen of humans, associated with upper and
lower respiratory tract infections in both children and adults (140). In particular, M.
catarrhalis tends to be associated with upper respiratory tract infections (including acute
otitis media and sinusitis) in children, but lower respiratory tract infections in adults
(usually with pre-existing pulmonary disease). Occasionally, the bacterium is reported as
being the causative agent of certain non-respiratory tract associated infections,
including: bacteremia (4, 70, 71, 126), endocarditis (187, 229), conjunctivitis/ keratitis
(1, 155, 257), and tracheitis (83). The organism has very occasionally been associated
with meningitis (63), ventriculitis (60, 215), ophthalmia neonatorum (197), acute
mastoiditis (151) and septic arthritis (2, 191). Interestingly, many reports have indicated
the seasonal incidence of M. catarrhalis infection, with the winter and spring months
showing the greatest rates of isolation (202, 218, 258). Moreover, this seasonality is not
a prominent feature of other commonly isolated respiratory tract-associated pathogens
e.g. Streptococcus pneumoniae and Haemophilus influenzae (64, 68, 143), and there is some
speculation that seasonal viral respiratory tract infection (e.g. respiratory syncytial virus
(9, 78) but not adenoviruses (12)) may be a pre-disposing factor in seasonal M.
catarrhalis infection. Another theory involves bacterial-bacterial competition involving
Corynebacterium spp. which form part of the normal human throat microflora (213).
From a clinicians’ perspective, it is also important to note that M. catarrhalis
may be isolated as part of a mixed population of pathogens. For example, research has
indicated that isolation of M. catarrhalis from sputa is accompanied with the isolation of
other bacterial pathogens on approximately 40-50% of occasions (the most common
being S. pneumoniae and H. influenzae)  (110, 188, 202). In such cases, it may be clinically
important to define the role of M. catarrhalis in the disease process, particularly with
respect to antibiotic therapy, i.e. should antibiotic therapy be targeted against the co-
isolated organism only, M. catarrhalis only, or should a broad spectrum antibacterial
agent be used.
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Childhood Infections
Otitis media - acute otitis media (AOM) is the most frequent infection
associated with M. catarrhalis in children (86, 88, 92, 93), and comprises inflammation of
the middle ear accompanied by a liquid effusion (145, 164). Approximately 50% of
children will have experienced at least one episode of AOM by their first birthday, and
this proportion rises to 70% by 3 years of age (144, 235, 236, 240), representing a
tremendous disease burden for this age group and necessitating the widespread use of
antibiotics (55, 200, 201). M. catarrhalis has been recognised as a specific pathogen
associated with AOM for over 70 years (111), being the third most common bacterium
isolated from this condition (behind H. influenza and S. pneumoniae) (58, 102, 193).
During routine visits, Faden et al (1994) (89), observed that otitis media prone children
were colonised in 44.4% of occasions compared to only 16.7% of occasions for otitis
non-prone children, suggesting a link between increased M. catarrhalis colonisation and
the occurrence of otitis media. Of note, the actual rate of M. catarrhalis associated AOM
may be underestimated, as tympanocentesis and culturing of middle ear effusions is not
routinely performed. The use of new PCR based methodologies also provides evidence
for the presence of M. catarrhalis in culture negative middle ear effusions from children
suffering chronic otitis media (203). Also of note, the development and use of vaccines
against H. influenza and S. pneumoniae could facilitate a future increase in the percentage
of AOM episodes attributable to M. catarrhalis. Historically, there appears to have been
a marked increase in the number of reported M. catarrhalis isolations from middle ear
effusions of children suffering from AOM since the 1980s (now approximating 15-
20%), an increase accompanied by the appearance of beta-lactamase producing strains
which now account for approximately 90-95% of all isolates (24, 147, 158, 194).
Further, there is some suggestion that M. catarrhalis may facilitate the spread of beta-
lactamase genes to other bacterial species during mixed bacterial infections (137). It is
perhaps poor consolation that the actual numbers of bacteria isolated from middle ear
effusions, and the severity of symptoms during AOM episodes, both appear to be
lower when M. catarrhalis is isolated rather than S. pneumoniae or H. influenzae (87).
Recent treatment recommendations for the treatment of acute otitis media were
presented by Hoberman et al (2002) (118).
Sinusitis – is another very common infection in childhood, which has been
estimated to account for approximately 5-10% of upper respiratory tract infections in
this age group (249-253). Diagnosis may be difficult due to the presence of fairly non-
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specific symptoms which are similar to allergy and upper respiratory tract viral disease
(62). Clinically, sinusitis may be divided into two groups, the acute group (where
symptoms persist for 10 to 30 days), and the subacute group (where symptoms persist
for 30 to 120 days). In both cases, M. catarrhalis accounts for approximately 5-10% of
bacterial infections, with S. pneumoniae and H. influenzae being more commonly isolated
pathogens (35, 46, 94). However, M. catarrhalis does grow poorly in environments
containing reduced oxygen concentrations (37).
Lower respiratory tract infections (LRTI) in children - the role of M, catarrhalis in
the aetiology of LRTI in children seems to be clear cut, the organism having been
isolated in pure culture from tracheal aspirates obtained from neonates, infants and
children with pneumonia (18, 20, 34, 109). Interestingly, M. catarrhalis appears to be
increasingly isolated from LRTI originating in hospitalised children, with Chong (1997)
(51) indicating an increase in lower respiratory tract infections in hospitalised children
from 11.4% in 1988 to 34.7% in 1995, a result possibly due to the increasing penicillin
resistance observed in M. catarrhalis isolates over this period.
Adult infections
Bronchitis and pneumonia - though not a common cause of lower respiratory
tract infection in healthy adults, M. catarrhalis may present a particular problem for
adults with pre-existing pulmonary disease and in the elderly. In particular, bacterial
exacerbations of chronic obstructive pulmonary disease (COPD) are often attributable
to S. pneumoniae, non-typeable H. influenzae and M. catarrhalis infection in that order (10,
34, 81, 166, 174, 188, 202, 224). Bacterial pneumonias attributable to M. catarrhalis tend
to be relatively mild, with the presence of patchy non-cavitary infiltrates on chest X-ray
(259). Particularly susceptible to M. catarrhalis pneumonia are patients with end-stage
pulmonary or malignant disease (14, 110), and many of these (>70%) are, or have been,
smokers (68). M. catarrhalis pneumonia may occasionally be complicated by bacteremia
(57, 126, 237).
Klingman et al (1995) (146) indicated that a proportion (approximately 20%), of
M. catarrhalis mediated bronchiectasis patients maybe chronically colonised with up to
four different strains of M. catarrhalis, though a direct relationship between the
exacerbation of bronchiectasis and M. catarrhalis isolation was not proven.
Laryngitis – M. catarrhalis appears to be the most frequent bacterial pathogen
associated with laryngitis in adults (220-222), though there remains some debate as to
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whether the organism actually infects or simply colonises adults presenting with
laryngitis (119). Further, the pathogenic potential of M. catarrhalis in laryngitic disease
has been suggested by the fact that laryngitis has been induced in an animal model
(128), and that patients with laryngitis are more likely to harbour isolates presenting
with a complement resistant phenotype (119).
BACTERIAL TYPING AND EPIDEMIOLOGY
Traditionally, typing of M. catarrhalis isolates (for determining the relatedness of
isolates during nosocomial transmission etc), has been performed using a series of non-
molecular techniques, which have included: susceptibility to human serum mediated
bacteriolysis, trypsin sensitivity/agglutination profiles against human group O
erythrocytes (227), iso-electric focussing of beta-lactamase proteins (186), serological
typing of lipopolysaccharide (241, 242), electrophoretic profiling of outer membrane
proteins (15, 178), autoaggregation properties (127), and a few other miscellaneous
techniques (65, 198, 199). However, advances in DNA technology now allows
comparative whole genomic testing to be performed. The simplest of these techniques
involves the use of restriction endonuclease enzymes to specifically digest the genomic
DNA of isolates, followed by gel electrophoresis to separate the individual fragments
(52, 142, 195). Hae III, Hind III, Pst I, Cla I and Spe I are particularly useful enzymes in
this respect. Particularly successful and popular at present is the use of macro-
restriction analysis (pulsed field gel electrophoresis or PFGE) which has been used to
type M. catarrhalis isolates, particularly in the nosocomial situation (112, 159, 160, 248,
261). Interestingly, the use of several genomic techniques, including strain specific
DNA probes (16, 254), automated ribotyping, and amplification fragment length
polymorphism (AFLP) analysis (30, 247), have all indicated the division of M. catarrhalis
isolates into 2 distinct phylogenetic clusters (or possibly sub-species). Moreover, M.
catarrhalis isolates expressing various virulence traits (complement resistance, increased
adherence to epithelial cells) have been found to be statistically associated with one of
these two clusters (30, 247). Such genomic typing studies have also shown the
genetically diverse nature of M. catarrhalis isolates, with successive clonal expansions
(often linked to geographical location) apparently occurring (82, 159). Inter-species
horizontal transfer of genes between M. catarrhalis and other species that inhabit the
same niche also appears possible (31, 154).
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Carriage and Spread
M. catarrhalis is an organism able to colonise the human respiratory tract
without causing disease, though there exists a striking difference between the carriage
rates of M. catarrhalis in children and in adults. In children, the carriage rate may be as
high as 75% (89, 101, 241, 243), whilst in adults the carriage rate is very low at around 1
- 3% (65, 76). This inverse relationship between rate of colonisation and age has been
known for approximately 100 years (11), and is still present today, though an adequate
explanation for this phenomenon still remains elusive. Based on evidence provided by
Meier and Stutzmann Meier (2003) (171, 231), one possible explanation for this
phenomenon is that colonisation is dependent upon the development of strain specific
mucosal immunoglobulin A (IgA), with specific IgA production being perhaps more
important than specific IgG production (77). In this scenario, multiple colonisation and
infection with different isolates of M. catarrhalis gradually increases the repertoire of
specific neutralising IgA (or IgG) antibodies, such that the number of novel M.
catarrhalis isolates able to colonise a particular individual decreases with time.
Alternatively, otitis prone children may fail to produce a broadly protective antibody
response (86), or could possibly have (sub-clinical) deficiencies in immune modulatory
genes. Whatever the explanation, there appears to be a distinct correlation between the
frequency of colonisation and the development of disease in children (38, 89, 92, 206,
241), a correlation which may also hold true for adults (146, 177).
There is as yet some debate regarding the mechanism of spread of M.
catarrhalis, with possible mechanisms including person-to-person transmission or spread
via environmental contamination (40, 125, 166). Both nursery schools and day care
centres may be important reservoirs for strain exchange in children (161, 205, 261), and
intra-familial spread has been observed(89). Outbreaks of nosocomial infection due to
M. catarrhalis have been regularly documented (Figure 4) (19, 59, 66, 109, 160, 196, 211).
However, the degree of (nosocomial) spread may be somewhat underestimated due to
the fact that M. catarrhalis colonisation may not always lead to the appearance of overt
disease (125).
Antibiotic Susceptibility
M. catarrhalis exhibits an almost universal resistance to penicillin related
antibiotics, with several recent studies indicating that world-wide, 90-100% of M.
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catarrhalis isolates produce beta-lactamase (3, 132, 136, 157, 173, 255, 264). This is a
striking statistic when one considers that before 1970 few isolates produced beta-
lactamase enzymes (44, 256). In fact, the increase in beta-lactamase producing isolates
has been so rapid that in most countries it appears that a “saturation point” is close to
being reached, with the increase in incidence of beta-lactamases positive M. catarrhalis
strains now levelling off at this very high level (133, 226, 264). Research into M.
catarrhalis beta-lactamase production has shown that 3 different isotype groups may be
identified, BRO-1, BRO-2 and BRO-3 (54, 79, 149). However, by far the most
common types are BRO-1 and BRO-2, being found in approximately 94% and 5% of
beta-lactamase producers respectively (45). There is some suggestion that BRO-1 is
gradually replacing BRO-2 over time (31, 85, 212) and that BRO-1 producing strains
are less susceptible to penicillins than BRO-2 producing isolates (124). Both BRO-1
and BRO-2 enzymes appear to be constitutively expressed, chromosomally or plasmid
encoded proteins, which differ by a single amino acid (32, 79, 80, 138). Interestingly,
there is some evidence to suggest that the BRO beta-lactamases of M. catarrhalis were
originally derived from a non-Moraxella species, this evidence includes: the lower G + C
content of the BRO encoding (bla) genes (31% compared to an average of 41%), and
the fact that the BRO-type beta-lactamases are lipidated in M. catarrhalis (suggesting a
Gram-positive origin for the gene) (29, 256). A simple restriction digestion
methodology to distinguish between the BRO-1 and BRO-2 beta-lactamase types has
been published (72). Of clinical relevance, isolates harbouring the BRO-1 encoding
gene tend to have higher transcription rates (and hence higher MICs) than BRO-2
harbouring isolates (137, 165). However, both BRO-1 and BRO-2 enzymes are
inactivated by beta-lactamase inhibitors (36, 98, 189). In any case, the choice of
treatment should ideally be based upon the type of disease and condition of the patient
(e.g. simple or complicated COPD) (184). It is however perhaps prudent for clinicians
to assume that all isolates of M. catarrhalis are resistant to penicillin, ampicillin,
amoxycillin, piperacillin and cephalothin (69, 137, 152). Also important for clinicians to
consider is the fact that the genes for BRO-type enzymes may be easily transferred by
conjugation between different species (139, 256), a phenomenon which may be
important in the treatment of mixed infections, and may even result in treatment failure
(120, 194, 228). That said however, there is some evidence to suggest that beta-
lactamase-producing Moraxella catarrhalis may actually prevent the emergence of
penicillin-resistant Streptococcus pneumoniae in children with recurrent acute otitis media
(131).
Chapter 2                                      Virulence, Genetic Variation, Immune Response and Putative Vaccines
24
M. catarrhalis isolates may also show some inherent resistance to trimethoprim,
with a recent study of 76 clinical isolates from Saudi Arabia indicating that 14.5% of
isolates were resistant to this antibiotic (137). Further, a recent survey showed that
approximately 10.5% of M. catarrhalis isolates in Latin America (130) and all isolates
from an Indian study (232) were highly resistant to combination therapy using
trimethoprim and sulphamethoxazole. In general however, M. catarrhalis isolates are
consistently susceptible to most non-beta-lactamase antibiotics including,
chloramphenicol, erythromycin, ciprofloxacin and gentamicin (17, 116, 117). Also,
fluoroquinolones remain very active against M. catarrhalis (67, 84). New antibiotics for
use against lower respiratory pathogens (including M. catarrhalis) are under constant
development and testing (33, 134).
THE IMMUNE RESPONSE
The immune response to bacterial pathogens is a highly complex process
involving both non-specific and specific mechanisms.
The Non-Specific Immune Response
Non-specific mechanisms include the presence of mucus and surfactant at
pulmonary surfaces, mucociliary action, alveolar macrophage activity and complement-
mediated lysis (238). Onofrio (1981) (192), published data looking at the removal of
several bacterial species from the lungs of mice, and in contrast to non-typeable H.
influenzae and Streptococcus spp., found that M. catarrhalis was cleared relatively slowly from
the lungs with a correspondingly significant increase (400x) in the numbers of
granulocytes. Further, the release of ''neutrophil defensins'' (peptides exhibiting broad-
spectrum antimicrobial activity and released by neutrophils as part of the inflammatory
process), have been shown to actually stimulate adherence of M. catarrhalis (107) (a
process conceivably involving the phase variable expression of bacterial adherence
genes). Finally, it has recently been reported that M. catarrhalis induces mast cell
activation and nuclear factor kappa B-dependent cytokine (IL-6 and MCP-1) synthesis
after direct contact with mast cells (with neither bacterial lipopolysaccharide or bacterial
supernatants inducing cytokine secretion) (148). The role of complement and
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complement resistance in the non-specific immune response to M. catarrhalis mediated
infections is discussed later.
The Specific Immune Response
Several studies have demonstrated the presence of bactericidal antibodies in M.
catarrhalis associated infections, including: AOM (90, 91, 150, 162), lower respiratory
tract infections (23, 47, 53), pneumonia (100) and exacerbations of COPD (13). Using
whole-cell M. catarrhalis bacteria as coating antigen and an ELISA assay format,
Goldblatt et al (1990) (105) showed that in the majority of cases, normal human sera
tested positive for the binding of IgG1, IgG2 and IgG3 sub-classes but not IgG4.
Further, the IgG3 sub-class of antibody may be particularly important in M. catarrhalis
infection (208) as IgG3 specific antibodies are low or undetectable in children under 4
years of age (48, 106). These findings may explain the differences in colonisation rates
observed between children and adults (11, 89). However, studies have indicated that
host Gm allotype (i.e. genetic markers present on IgG molecules) may influence the
IgG subclass composition of specific antibody responses to M. catarrhalis outer
membrane proteins (42), possibly via a complex interaction between B-cells, T-cells,
HLA type and Gm-linked V region antibody expression (104). If the IgG3 sub-class is
particularly important and allotype variation results in differences in IgG3 expression in
certain individuals, then this could explain why some children suffer from chronic M.
catarrhalis infections (e.g. chronic otitis media)
At mucosal surfaces IgA antibody responses predominate and specific IgA has
been detected in middle ear effusions of children with otitis media (90, 141, 233) and in
the saliva of healthy adult volunteers (171). Stutzmann Meier (2003) (231) indicated that
M. catarrhalis colonisation in early infancy was associated with a consistent IgA immune
response directed against the outer membrane proteins. However, it has been shown
that the development of (mucosal) IgA antibody may not necessarily correspond to the
development of (systemic) IgG antibody (216, 230). Of note, Mandrell et al (1992)
(156) and Troncoso et al (2004) (239) identified cross-reactive antigens between M.
catarrhalis, N. meningitidis and N. lactamica, and showed the presence of cross-reactive
antibodies in both healthy individuals and patients convalescing from meningococcal
meningitis.
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SERUM AND COMPLEMENT RESISTANCE
The complement system is a complex series of proteins found in serum which
are part of the host defense mechanism against microbial pathogens (43, 153). It is
known that the ability of Gram-negative bacteria to withstand the effects of
complement is an important virulence factor (39, 214), and many M. catarrhalis disease
causing isolates are apparently resistant to the effects of complement in human serum
(121, 122, 135). Several studies have shown the importance of complement resistance
to M. catarrhalis pathogenicity (37, 176, 227), with isolates from the upper respiratory
tract of children or healthy adults tending to be complement sensitive, whilst isolates
from children and adults with lower respiratory tract infections tending to be
complement resistant (122, 244). There appears to be no relationship between beta-
lactamase production (another virulence factor) and complement resistance in M.
catarrhalis (223), possibly reflecting the plasmid borne nature of beta-lactamase
production or the multifactorial nature of complement resistance. Our knowledge
regarding complement resistance mechanisms in M. catarrhalis is as yet limited. Prellner
et al (1980) (204), provided evidence for high level binding of  C1q complement
component to M. catarrhalis, a phenomenon which would render the organism sensitive
to the anti-bacterial activity of complement. Research by Verduin et al (1994) (245),
showed that a least one resistance mechanism involves inhibition of formation of the
membrane attack complex of complement, involving the binding of vitronectin (a
natural inhibitor of complement found in serum) to the UspA2 protein present on the
surface of M. catarrhalis (169, 246). An M. catarrhalis mutant lacking the UspA2 gene was
found to be sensitive to complement-mediated killing, whilst the parent isolate was
resistant (6). Further, UspA2 protein shares similarity with the H. ducreyi DsrA (ducreyi
serum resistance protein A), which has also been shown to be involved in serum
resistance (56). A copB gene knockout M. catarrhalis mutant was used by Helminen et al
(1993) (114) to show that reduced expression of the CopB (or OMP B2) iron
acquisition protein, decreased serum resistance and survival in vivo. Confusingly
however, Furano et al (99), recently indicated that constitutive expression of iron-
regulated proteins (via inactivation of the ferric iron uptake regulator gene fur) actually
increases the susceptibility of M. catarrhalis to the bactericidal activity of normal human
sera, and suggested that this most probably occurs due to the up-regulated expression
of (outer membrane) proteins increasing the presence of multiple antigenic targets for
human antibody binding and hence complement activation. One further study of M.
Chapter 2                                      Virulence, Genetic Variation, Immune Response and Putative Vaccines
27
catarrhalis outer membrane protein expression indicated that OMP E (a putative fatty
acid transporter) may be involved in serum sensitivity (179). In 2000, Zaleski et al (263)
implicated the M. catarrhalis LOS in complement resistance, as inactivation of the galE
gene which encodes a UDP-glucose-4-epimerase (involved in the biosynthesis of LOS)
resulted in enhanced serum susceptibility of the mutant. Interestingly, similarities in
outer membrane proteins and LOS between M. catarrhalis and Neisseria spp. (e.g. N.
gonorrhoea and N. meningitidis), may provide further clues as to the mechanisms by which
complement resistance is mediated in M. catarrhalis .
 Finally, several studies have indicated that complement resistant and
complement sensitive isolate of M. catarrhalis may actually represent two different sub-
species (30, 247).
PUTATIVE VACCINE CANDIDATES
Currently, the efforts of many researchers in the M. catarrhalis field is geared
towards the identification and development of specific vaccine candidates (reviewed in
(167, 168, 170)) with particular emphasis being placed on 1) the
lipooligosaccharide/lipopolysaccharide  (LOS/LPS) and 2) various highly expressed
outer membrane proteins (178).
Several studies have indicated that an antibody response to the LPS of M.
catarrhalis is generated and that this response is not serotype specific but directed against
common epitopes present on the LPS (95, 129, 190, 209), though confusingly there is
some evidence to suggest that the antibody response (in rabbits) is indeed serotype
specific (207). This LPS antibody response appears to be particularly directed against
the oligosaccharide region of the LPS (73-75). The inoculation of non-viable M.
catarrhalis into the middle ear bullae of guinea pigs also induces middle ear inflammation
and mucoperiosteal histopathology, a type of inflammatory picture most probably
mediated by bacterial outer membrane components (including the LOS) (219). Based
on this data, research by several groups has indicated that the LPS/LOS may be a
promising vaccine candidate so long as its inherent toxicity is removed and it is linked
to a protein conjugate to improve immunogenicity (108, 123, 129, 234). To complicate
matters, there are at least 3 serotypes of LPS, each exhibiting some form of cross-
reactivity (242), possibly dependant on differences in the lengths of the immuno-
dominant oligosaccharides (75). However, no relationship between serotype and
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severity of infection have been noted, implying that all three of these common LOS
serotypes (types A, B and C) should ideally be included in a future LPS/LOS based
vaccine.
Most research regarding the development of a vaccine against M. catarrhalis has
concentrated on the identification and investigation of several major outer membrane
proteins (OMPs), which currently fall into roughly 2 distinct groups. One group
includes OMPs associated with bacterial adherence, including; UspA1/2 (7, 48, 49,
115), OMP CD (182, 183, 260) and MID (96, 97), whilst the other group includes
OMPs associated with iron and fatty acid (nutrient) acquisition,  LbpA, LbpB, TbpA,
TbpB/B1/74kDa protein (25, 27, 28, 41, 50, 163), CopB  (8, 114, 225) and OMP E (21,
179).
The UspA proteins (UspA1 and UspA2) are closely related proteins which
share some conserved, semi-conserved and repeat sequence domains (7, 61, 112). Both
proteins share a conserved epitope that binds the monoclonal antibody 17C7
(mab17C7), which could be useful in the progress towards a M. catarrhalis vaccine (172).
Moreover, both proteins appear to elicit (protective) antibodies in humans (48, 216,
217, 231), mice (115, 169) and guinea pigs (49). OMP CD is a protein which has been
shown to specifically bind human middle ear and nasal mucins but not salivary mucin
(210), and exhibits a high degree of sequence conservation (181, 260). The protein has
also been shown to be a target for both the mucosal and systemic immune response
(183). However, the degree of sequence conservation in OMP CD could indicate that
this protein does not actually come under immuno-selective pressure in vivo, and may
therefore not actually be a good vaccine candidate in humans. A recent study has also
indicated that a 200kDa IgD binding protein (MID) is also an adhesin (96) able to
induce human B-lymphocyte (but not T-lymphocyte) activation (103). This protein also
appears to be conserved and is apparently present in most M. catarrhalis isolates (175).
However, the usefulness of this MID protein as a future vaccine candidate has yet to be
determined.
Studies have shown that M. catarrhalis expresses two lactoferrin receptors
(LbpA and LbpB) (26) and two transferrin receptors (TbpA and TbpB*/OMP B1)
(185). Yu (1999) (262) showed that of these four iron acquisition proteins only the
LbpB  and TbpB proteins show strong reactivity with acute- and convalescent- phase
sera from  patients with M. catarrhalis associated pulmonary infections. Moreover, there
appeared to be considerable antigenic heterogeneity in reactivity to the TbpBs and
LbpB proteins isolated from different M. catarrhalis isolates. CopB (also known as OMP
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B2) is an iron-repressible 81kDa outer membrane protein which is largely conserved
between M. catarrhalis isolates with discrete regions of moderate heterogeneity (225). A
copB binding monoclonal antibody (Mab10F3) was shown to enhance the pulmonary
clearance of M. catarrhalis in a mouse model and was able to bind to 70% of M.
catarrhalis isolates tested (5, 114). Moreover, significant rises in anti-copB antibody titres
were observed in patients with M. catarrhalis infections (113, 162, 171). OMP E exhibits
weak homology to the fatty acid transporter FadL of E. coli (21). The 47kDa protein
appears to be highly conserved among M. catarrhalis isolates (180), and a majority of
patients with chronic bronchitis were shown to have IgA antibodies to OMP E in their
sputum, (though surprisingly none of ten adults with M. catarrhalis lower respiratory
tract infections demonstrated a clear-cut rise in OMP E antibody titter) (22). Further,
two M. catarrhalis gene knockout mutants lacking OMP E were shown to be more
readily killed by normal human serum compared to the isogenic parent strains (179).
*N.B. Several groups have independently worked with the TbpB protein, such that two
other names exist for TbpB, namely B1 (41) and 74kDA protein (50).
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ABSTRACT
Pulsed field gel electrophoresis typing was performed on a retrospective set of
129 Moraxella catarrhalis isolates obtained over a 20 month period from 70 children
admitted to, or presenting at, the Erasmus University Medical Center, Rotterdam, The
Netherlands. The mean age of the children (at the end of the study) was 2.5 years with
an age range of between 6 months to 15 years. 51 different M. catarrhalis types were
isolated from the hospitalised children, with 31% (22/70) being infected with two
particularly prevalent M. catarrhalis types. These two prevalent types also exhibited
different protein profiles. 72% (16/22) of the children infected with these two
predominant types had spent at least one week on two paediatric intensive care wards.
No exacerbation of existing disease or new disease was observed in children for whom
M. catarrhalis type changes occurred.
INTRODUCTION
Moraxella catarrhalis is often found as a commensal bacterium of humans,
though the species has also been recognized as a major respiratory pathogen of both
children and adults (Verduin et al., 2002). The organism is most often associated with
the respiratory disease states of : acute and chronic otitis media (Faden, 1995; Faden et
al., 1997), sinusitis (Finegold et al., 2002) and acute exacerbations of chronic obstructive
pulmonary disease (COPD) (Pfaller et al., 2001; Sethi and Murphy, 2001). In common
with several other respiratory pathogens, M. catarrhalis has the ability to adhere to
bronchial epithelial cells, facilitate ciliotoxicity and ultimately damage pulmonary
epithelia (van Alphen et al., 1995), all of which add to the pathogenic potential of this
species.
Nosocomial pneumonia is the most frequently acquired infection in the
intensive care unit (ICU) setting and the second most frequently acquired infection in
hospitals overall (Lode et al., 2000). In ventilated children who contract nosocomial
pneumonia, an attributable mortality of 27% may be observed (rising to 43% where
Pseudomonas or Acinetobacter species are cultured) (Fagon et al., 1993).  Reports of
nosocomial infections due to M. catarrhalis have already been published (Cook et al.,
1989; Denamur et al., 1989; Kasian et al., 1989; Morgan et al., 1992; Patterson et al.,
1988; Richards et al., 1993), with Ikram et al. (1993) indicating that the average length
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of stay in hospital is considerably longer for children colonized with M. catarrhalis
compared to those not colonized and providing evidence that re-colonization with
different M. catarrhalis types occurs. Recently, it has been observed that the isolation of
a new strain of S. pneumoniae, H. influenzae or M. catarrhalis is associated with a
significantly increased risk of experiencing an exacerbation of chronic obstructive
airways disease in adults (Sethi et al., 2002).
The aim of this study was to retrospectively assess M. catarrhalis population
diversity/dynamics in hospitalized children and to determine if M. catarrhalis type
changes resulted in exacerbation of existing disease within this particular study
population.
MATERIALS AND METHODS
Study population.  M. catarrhalis isolates were collected retrospectively from
70 children admitted to, or presenting at, the Erasmus Medical Center, Rotterdam, The
Netherlands during the study period of July 2000 to March 2002. Sixty one of these
seventy children had been admitted to diverse pediatric wards within the hospital
(including neonatology, pediatric intensive care, children’s surgery and children’s health
departments) for various periods of time. Nine children had attended outpatient clinics
and had not been admitted to the Erasmus Medical Center between the beginning of
the study (July 2000) and the date of isolation of the first positive culture. All of the
children lived in geographically diverse regions within The Netherlands and suffered
from unrelated disease states (e.g. tetralogy of Fallot, HIV positive, Down syndrome
etc). The mean age of children from which isolates were obtained was 2.5 years with an
age range of between 0.5 to 15 years.
M. catarrhalis specimens. One hundred and twenty nine retrospectively
cultured and stored M. catarrhalis isolates, (which had been isolated from routine
swabs/swabs taken from children presenting with overt signs of disease over a 20
month study period) were collected ready for typing. During the time period of the
study, 4 or more M. catarrhalis culture positives were available from 10% (7/70) of the
children, with only a single positive culture being available from 76% (53/70) of the
children.  M. catarrhalis positive cultures came from 79 sputa, 38 bronchial aspirates, 9
bronchial lavages, 1 eye swab, 1 nose swab and 1 drain tip.
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M. catarrhalis typing. Pulsed field gel electrophoresis (PFGE) was performed
as detailed by Verduin et al (Verduin et al., 2000). PFGE patterns were analyzed using
GelCompar software (Applied Maths, Gent, Belgium) with band tolerance set at 2.5%
after gel lanes had been normalized against a lambda DNA ladder. Sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using a
discontinuous Laemmli buffer system  (4% stacking gel and 11 % separating gel) and
the Mini-PROTEAN 3 Cell electrophoresis kit (Bio-Rad, USA). Eight M. catarrhalis
isolates of PFGE type E or M (4 from each group) were chosen at random for SDS-
PAGE analysis.
Clinical data. Clinical data was collected from patients’ clinical records
containing details of existing disease, dates and wards to which children were admitted,
dates discharged from hospital, any treatment procedures (e.g. decanulation,
extubation), any reports of exacerbation of disease (e.g. increased mucus, fever) and
bacterial/viral investigations (e.g. bacterial culture, viral immunofluorescence).
RESULTS AND DISCUSSION
Diversity in M. catarrhalis types. During the twenty month study period (i.e.
July 2000 to March 2002), a total of 51 different types of M. catarrhalis were isolated
from seventy children admitted to, or presenting at the Erasmus Medical Center. Of
these 51 types, 4 different types (8%) were each isolated from two distinct children, and
two “predominant” types (types E and M) were isolated from fifteen (21%) and nine
(13%) children respectively (Figure 1).
Figure 1. Venn diagram showing the
number of different children colonized with
particular M. catarrhalis pulsed field gel
electrophoresis (PFGE) pattern types.
Letters = PFGE types. Numbers = number
of individual children infected with that
particular PFGE type. 40 = number of
children in which only a single PFGE type
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The dendrogram generated when these 51 different M. catarrhalis types were
compared is shown in Figure 2; multiple isolates of the same type from the same child
were removed in order to generate a more accurate view of the diversity of M. catarrhalis
types present within the study population. A large number of individual M. catarrhalis
PFGE types were observed within the study population of hospitalized children. This
large number of types probably reflects the high degree of genetic diversity present
within this species, a diversity which appears to be a feature of M. catarrhalis infection
and colonization (Faden et al., 1994; Hays et al., 2003; Martinez et al., 1999) and which
may present problems for vaccine design. However, despite this diversity, two distinct
but closely related clusters of PFGE types (types E and M) could be observed within
the dendrogram of isolates.
Upon SDS-PAGE analysis of 4 randomly chosen isolates from groups E and
M (Figure 3), it was observed that individual isolates within the E and M clusters also
shared similar protein profiles and that these protein profiles differed between the two
E and M clusters.  The presence/absence of an approximately 40 kDa protein was
particularly noticeable. The inclusion of PFGE banding patterns obtained from four
randomly selected complement sensitive and complement resistant isolates (acquired
from Verduin et al., 2000) to the dendrogram shown in Figure 2., indicated no grouping
of complement resistant or sensitive PFGE banding patterns to one or other of the
clusters E / M, or to any particular region of the dendrogram (data not shown).
The hospital setting. Examination of M. catarrhalis type data and hospital
location, indicated that diverse types could be found on all children’s wards of the
hospital. Moreover, though two dendrogram clusters of PFGE types could be
observed, neither of these clusters was found to be100% associated with children
admitted to any particular ward. However, more specific analysis, showed an
association between isolation of the predominant types E and M and admission of
children for one week or more to two adjacent pediatric intensive care wards (Table 1.).
By comparing the number of children colonized with type M and admitted to
pediatric intensive care wards compared with children colonized with type M and
admitted to other wards, it was found that colonization by type M was statistically
associated to the pediatric intensive care wards (2-tailed Fisher’s Exact test p < 0.01),
though colonization of children with type M was not absolutely dependent on a stay of
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FIG. 2.  Dendrogram showing pulsed field gel electrophoresis (PFGE) patterns of M. catarrhalis isolates
obtained from children admitted to or attending a hospital in the Netherlands. PFGE was performed as
detailed by Verduin et al 2000 and patterns were analyzed using GelCompar software(Applied Maths, Gent,
Belgium) with band tolerance set at 2.5% after gel lanes had been normalized against a lambda DNA
ladder. Letters E and M represent isolates with similar PFGE patterns which were subsequently grouped
into M. catarrhalis types E and M.
Figure 3. SDS-PAGE protein profiles obtained using four randomly chosen M.
catarrhalis type M isolates (numbers 1- 4) and four randomly chosen M. catarrhalis type
E isolates (numbers 5 - 8). Arrow  = major difference in protein band profile
observed between types E and M.
TABLE 1. M. catarrhalis pulsed field gel electrophoresis type and length of stay for 70 children admitted to
or attending a Dutch hospital.
< 1 week
Time spent on wards other
than pediatric intensive care
> 1 week< 1 week > 1 week
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greater than one week in pediatric intensive care (2-tailed Fisher’s Exact test p = 0.067).
Of the four other M. catarrhalis types isolated from more than one child (Figure 1.); type
aA was associated with 2 children admitted to the pediatric intensive care wards (where
types E and M were predominant), type bI was isolated from two children who were
admitted to the same neonatology ward, and types aP and aW were isolated from
children with no common link. It is possible that a larger study would indicate that
other PFGE types are statistically associated with the pediatric intensive care setting, or
that colonization of children with the same M. catarrhalis type is not only restricted to
the pediatric intensive care setting. It should also be noted that there might have been a
natural bias towards the isolation of common types within the two pediatric intensive
care wards. This results from the larger number of swabs regularly taken from the
children admitted to these two wards. However, this possible bias does not affect our
results regarding the diversity and dynamics of M. catarrhalis types isolated from
hospitalized children. We may have merely underestimated the extent of M. catarrhalis
dynamic type changes within this environment.
M. catarrhalis type switching. Based on the findings of Table 1., a timeline
could be drawn for children admitted to the two pediatric intensive care wards and
colonized with types E and M during the course of the study (Figure 4). Using this
timeline, a dynamic relationship was observed between these two dominant types and
an important time period (between February and April 2001), where type switching had
occurred. The actual mechanism underlying this type switching is not fully understood,
though three possible mechanisms are possible; 1) changes in the dominant type
present within a population of organisms colonizing a single individual leads to
isolation of different types from that individual over different time frames, 2) a new
(potentially more virulent) type is introduced into the hospital from the outside
community and colonizes hospitalized individuals/health care workers e.g. during the
visiting hours, or 3) transfer of types occurs within the hospital environment per se e.g.
from child to child or from health care worker to child. Interestingly, isolates from
child p77 showed switching between types E and M within the same month on several
occasions (Figure 4), possibly indicating that a mixed population of M. catarrhalis types
may have colonized this particular child (repeated cycles of infection, involving
clearance and re-infection with these two types seems unlikely as the child had an intact
immune system). However, with regard to community and hospital spread of types, of
thirty seven M. catarrhalis isolates from children who had not been admitted to the two
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pediatric intensive care wards where types E and M were predominant, 14% (5/37) of
children were colonized with M. catarrhalis type E, indicating that type E was circulating
either within the community or within the whole of the hospital during the time-course
of the study. In contrast, type M was only ever isolated from the pediatric intensive care
wards, indicating that the spread of this particular type was most probably occurring
within these wards themselves. With reference to this data and the timeline of Fig 4., it
seems likely that child p77 may have been the index case for the spread of type M
within these pediatric intensive care wards. Certainly, the previous transmission of
viruses from child to child and/or child to health care worker in a neonatal and
pediatric intensive care unit has been documented (Gagneur et al., 2002a; Gagneur et
al., 2002b).    
Figure 4. Timeline showing the dynamic population changes observed between M. catarrhalis
PFGE types E and M in hospitalized children on two geographically linked pediatric intensive care wards.
Filled rectangles = child not yet born. Letters = pulsed field electrophoresis type. p23 = child number 23. *
= both PFGE types E and M were isolated during these months. #   = this isolate was cultured from a child
who had previously been admitted to pediatric intensive care but at the time of M. catarrhalis culture was
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Changes in M. catarrhalis type and clinical data. Analysis of clinical data,
showed no obvious new treatment procedures taking place on the pediatric wards
during the period of the study, and no other epidemic infectious agents (e.g. bacteria
and viruses such as Mycoplasma pneumoniae, Parainfluenzaviruses etc) had been isolated
from the wards. Also, no link was found between change in M. catarrhalis type and
isolation in “pure” culture of M. catarrhalis, or change in M. catarrhalis type and isolation
in combination with other bacterial pathogens (e.g. H. influenzae, P. aeruginosa, S. aureus
etc). No change in antibiotic resistance profiles occurred after a change in M. catarrhalis
type, with both types E and M being resistant to penicillin and ampicillin but sensitive
to augmentin, ceftriaxon and tetracycline. During the 20 month time period of the
study, several other infectious agents were isolated from one or more of the
hospitalized children. These infectious agents included among others cytomegalovirus,
parainfluenzavirus type 3, enterovirus, respiratory syncytial virus etc. Interestingly, the
clinical data showed that one child (p29) had been diagnosed with pneumonia whilst
admitted to one of the pediatric intensive care wards. This child had recently undergone
surgery to repair patent ductus arteriosus of the heart and both M. catarrhalis and S.
aureus were isolated from consecutive sputum samples. However, the M. catarrhalis
cultured from this child was not PFGE type E or M (Figure 2.) and the child was
discharged in good health approximately 3 weeks later. Adults with chronic obstructive
pulmonary disease (COPD) have been previously shown to develop new serum IgG
and new mucosal IgM to M. catarrhalis after exacerbations (Bakri et al., 2002). Moreover,
a recent study has indicated an association between the isolation of a new strain of a
particular bacterial species (including M. catarrhalis) and exacerbation of chronic
obstructive pulmonary disease in adults (Sethi et al., 2002). However, our own studies
of available clinical records, indicated no link between the acquisition of a new M.
catarrhalis type and subsequent exacerbation of existing disease (or development of new
disease) within hospitalized children.
These results indicate that dynamic nosocomial M. catarrhalis population
changes occur in individual hospitalized children over time, and that these changes are
set against an already genetically diverse background of M. catarrhalis types. In contrast
to recent results, no relationship could be determined between change in M. catarrhalis
type and exacerbation of disease. However, more detailed and rigorously controlled
studies would be useful in assessing the exact effect of M. catarrhalis type changes on
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child morbidity, as well as helping to elucidate the mechanism by which such
population changes occur.
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Pneumococcal vaccination does not affect the genetic
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Moraxella catarrhalis is an acknowledged pathogen of the respiratory tract in
both adults and children [1], occupying a similar niche to that of Streptococcus pneumoniae
(the “pneumococcus”) and Haemophilus influenzae. In a recent study, Veenhoven et al [2],
showed that toddlers and older children (who had previously experienced episodes of
acute otitis media (AOM)) when vaccinated with a conjugate pneumococcal vaccine
followed by a polysaccharide pneumococcal vaccine, did not experience a reduction of
AOM episodes. Further, isolations of M. catarrhalis did not differ between the two
groups, but Staphylococcus aureus was isolated more often in the vaccinated group than in
the control (hepatitis B or A) vaccinated group (p = 0.02). It was also noted that an
“immediate and complete” replacement of S. pneumoniae vaccine serotypes by non-
vaccine serotypes tended to occur within the vaccinated group. As bacterial interference
of M. catarrhalis by competing Streptococcal species has been demonstrated in vitro [3], the
aim of this study was to determine whether vaccination against S. pneumoniae (and hence
its removal from the M. catarrhalis niche) had an effect in altering the genetic diversity of
M. catarrhalis isolates compared to a control vaccinated group.
During the course of the study, children were followed for a total of 18
months, with routine microbiological and clinical investigation occurring 1, 7, 14, 20
and 26 months after vaccination as well as during any episode of AOM. Bacterial
cultures were obtained from nasopharyngeal swabs at routine visits and also from
middle ear fluids during episodes of AOM. In total, 41 M. catarrhalis isolates obtained
from 13 children vaccinated with pneumococcal vaccine and 21 M. catarrhalis isolates
obtained from 6 children vaccinated with a control (hepatitis A or B) vaccine were
genotyped using pulsed field gel electrophoresis (PFGE), as described by Verduin et al
(2000) [4]. The results of PFGE analysis are presented as a dendrogram in Fig. 1. As an
indication of pathogenic potential, all isolates were also tested for the phenotypic
expression of complement resistance using the ”culture and spot” test [5].
PFGE analysis of the isolates indicated the presence of four clusters
comprising a wide range of genotypes. The high degree of diversity within the M.
catarrhalis species has already been documented in several publications [6, 7]. No pattern
could be observed between PFGE cluster and vaccination status, or PFGE cluster and
the isolation of other (co-colonizing) bacteria. M. catarrhalis PFGE types belonging to
different clusters were found to occur within the same patient over time (e.g. patient
1001), this observation also holding true for PFGE types associated with episodes of
AOM (e.g. patient 4025).
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1      V       1         2020     R       S+H
1      V       7         2020     R         H
2      V    14/20*   3001     R         --               --
1      V       1         2040     R         H
1      V       7         2040     R          S
1      V      26        2020     R         H
1      V      14        2040     R       S+H
5      V       7         4002     R         --
5      V      26       4002      R       S+H
1      V       7         1001     R       S+H
2      V      20        3001     R       S+H
4      H       1         3031     R       S+H
1      V      14        2020     R         --
4      H       7         3031     R       S+H
2      V      26        3001     R       S+H
4      H      14        3031     R         S
5      V      14        4002     R         --
   OTHER
ORGANISM
A   V/H   T          P      C       NS         MEF
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Fig. 1  Dendrogram showing relatedness of M. catarrhalis PFGE types isolated from an S. pneumoniae
vaccine trial. Middle ear fluids were only collected during acute otitis media episodes. A = age after final
vaccination. V/H = vaccinated S. pneumoniae / vaccinated Hepatitis A or B.  T = time of routine planned
visit after final vaccination, where 1, 7, 14, 20 and 26 = 1, 7, 14, 20, 26 months respectively. 7/14 etc =
acute otitis media occurring between routine visits of 7 and 14 months etc.  P = patient. C = complement
phenotype, where R = resistant and S = sensitive. NS = nose swab. MEF = middle ear fluid/swab. * =
culture from middle ear fluid after an acute otitis media episode. S = Streptococcus pneumoniae. H =
Haemophilus influenzae. A = Staphylococcus. aureus. NF = non-lactose fermenter. M = a second M. catarrhalis
PFGE type isolated at the same time but from another site.  # = M. catarrhalis of same PFGE type isolated
from this site.  -- = no organism isolated.
The vast majority of isolates 90% (56/62) were found to be resistant to the
effect of complement in human serum, and there was no difference between the
isolation of complement resistant and sensitive phenotypes between the two vaccinated
groups (Fisher’s Exact Test p = 1). The percentage of complement resistant M.
catarrhalis isolated appears to be relatively high when compared to some studies
involving healthy children (90% versus 30 -60% respectively [8]), though other studies
have yielded similar results [9]. The percentage complement resistant isolates could
have been influenced by the fact that the children enrolled on the study had previously
experienced episodes of AOM disease, possibly resulting in an enhanced immune
response (including complement mediated responses) against potential bacterial
pathogens.
In this study, vaccination against S. pneumoniae in older children did not affect
the diverse genetic nature of M. catarrhalis isolates cultured when compared to a control
vaccinated group.
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Abstract
Previous research has shown that a genetically distinct subpopulation/lineage
of Moraxella catarrhalis exist which are associated with virulence traits. Therefore, the
development of an assay, which could distinguish between different Moraxella catarrhalis
lineages, would be advantageous in identifying isolates with an increased virulence
potential. In this study, both intensive whole-cell genomic analysis and one-dimensional
protein expression profiling was performed on 25 complement resistant and 23
complement sensitive isolates of Moraxella catarrhalis in order to identify markers
associated with both genetic lineage and complement phenotype (a model for virulence
potential). High-throughput amplified fragment length polymorphism (htAFLP)
analysis generated 2,273 fragment length polymorphisms, with an average of 862
polymorphisms per isolate, revealing the presence of two phylogenetic lineages and 40
lineage-specific markers. However, no complement phenotype-specific polymorphisms
were found, though 361 polymorphisms (16%) were found to be significantly
associated with complement phenotype (Fisher’s exact test P < 0.05). Simple one-
dimensional SDS-PAGE analysis revealed the presence of 6 major protein expression
profile markers significantly associated with either the complement resistant or sensitive
phenotype (Fisher’s exact test p<0.01). Subsequent sequencing and MALDI-TOF
analysis of a number of genetic and protein markers revealed that most markers
originated in housekeeping genes. However, genetic markers associated with a putative
competence protein and major outer membrane protein CopB, as well as the
differential expression of an outer membrane hemagglutinin (Hag) were observed.
1. Introduction
Moraxella catarrhalis is a commensal of the human respiratory tract, which is also
recognized as a pathogen of both children and adults. Carriage rates differ widely
between children and adult populations, being approximately 77.5% and 2%
respectively [1,2]. In children, the organism has been associated with acute otitis media
[3], sinusitis [4], and infrequently pneumonia [5] and bacteremia [6]. Isolates appear to
spread in children via nursery schools and day care centers [7], though respiratory tract
colonization by a new M. catarrhalis genotype does not necessarily result in the
production of overt disease [8]. In adults, the organism has been associated with
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exacerbations of chronic obstructive airways disease (COPD) / bronchitis [9,10], and
pneumonia [11].
Previous studies using a variety of different DNA typing techniques,
including PFGE/RAPD [12], and single-adapter AFLP (sAFLP) / probe-generated
RFLP (pRFLP) / 16S rRNA sequencing [13],  have suggested that genetic lineages or
sub-populations of M. catarrhalis isolates exist [14], and that these lineages exhibit
different virulence potentials. One particularly important virulence factor is that of
complement resistance [15-18], with evidence suggesting that the mechanism of
resistance may be facilitated via inhibition of membrane attack complex (MAC)
formation, possibly by the binding of the complement inhibitor vitronectin to particular
forms of the bacterial ubiquitous surface protein A2 (UspA2) [19-23]. However, this is
not the only mechanism that has been described, as the iron acquisition protein CopB
[24,25], a 50kDa outer membrane protein OmpE [26], a lipooligosaccharide P(k)
epitope [27], as well as a ferric uptake regulator (fur) [28], have also been implicated in
facilitating complement resistance.
In this study, detailed whole-cell genomic analysis (high-throughput
amplification fragment length polymorphism), and one-dimensional protein expression
profiling was performed, in an attempt to identify lineage and complement phenotype-
specific markers which could be useful in the development of assays able to distinguish
between different virulent M. catarrhalis lineages, especially those exhibiting an increased
pathogenic potential.
2. Materials and methods
2.1. Bacterial isolates
Twenty five complement resistant and 23 complement sensitive isolates of M.
catarrhalis were chosen from the collection of isolates within the Department of
Microbiology and Infectious Diseases at the Erasmus MC, Rotterdam, The Netherlands
(Table 1). These isolates had been previously characterized using several genotyping
techniques by Verduin et al [12]. The Dutch isolates used were considered
representative of the M. catarrhalis isolates circulating within The Netherlands during the
time period 1989 - 1997.
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Table 1 
M. catarrhalis isolates used in htAFLP analysis
NN = isolates from children at a primary school, Nieuwegein, The
Netherlands (1989). HN = isolates from children at a primary school,
Heerenveen, The Netherlands (1993). FN = clinical isolates from adult
lower respiratory tract infections, Friesland, The Netherlands (1993). UN
= positive blood cultures from children, Utrecht, The Netherlands (1989).
RN = positive blood cultures from children, Rotterdam, The Netherlands
(1997). ATCC = Isolate from the American Type Culture Collection. A =
Ghanean isolates (1995)
Complement Complement
Isolate Origin Phenotype Isolate Origin Phenotype
1.9 NN Sensitive F3.57 HN Sensitive
1.12 NN Resistant F4.64K HN Sensitive
1.24 NN Resistant F4.64N HN Sensitive
1.38 NN Resistant F5.82 HN Resistant
1.39 NN Sensitive F6.90 HN Resistant
3.9 NN Resistant F6.92 HN Resistant
3.14 NN Sensitive F6.93 HN Sensitive
3.18 NN Sensitive 38935 FN Sensitive
3.21 NN Sensitive 55183 FN Sensitive
3.24 NN Sensitive 60832 FN Sensitive
4.16 NN Resistant 69982 FN Sensitive
4.22 NN Sensitive 129822 FN Resistant
5.12 NN Sensitive 131472 FN Resistant
6.2 NN Sensitive H2 UN Resistant
6.12 NN Sensitive H12 UN Resistant
7.2 NN Sensitive 97/951 RN Resistant
7.10 NN Sensitive 97/0233 RN Resistant
7.13 NN Resistant 25240 ATCC Resistant
8.3 NN Sensitive B22 A Resistant
F1.3 HN Resistant D14 A Resistant
F1.11 HN Sensitive F17 A Resistant
F2.42 HN Sensitive Q01 A Resistant
F2.44 HN Resistant R02 A Resistant
F3.46 HN Resistant V02 A Resistant
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2.2. Complement resistance testing
The complement resistant or sensitive phenotype of the 48 M. catarrhalis
isolates used in this study had been previously determined using the “culture-and-spot”
test by Verduin et al [29]. This is a rapid and simple test for determining the
complement resistance phenotype of M. catarrhalis, which exhibits a statistically
significant concordance with the serum bactericidal assay (P < 0.0001). For the
purposes of this publication any isolate determined as expressing the intermediate
complement resistant phenotype using the “culture and spot” test (isolates F5.82, 1.24
and F6.92) was regarded as complement resistant.
2.3. Whole-cell genomic htAFLP and phylogenetic analysis
High-throughput AFLP (htAFLP) analysis was performed at Keygene N.V.
(Wageningen, The Netherlands), using primers labeled with radioactive phosphorous-
33 as previously described [30]. Genomic DNA was digested using the restriction
enzymes MboI and MseI, heat inactivated, and MseI and MboI adapters ligated to the
restriction products. htAFLP amplification was subsequently performed using i) an
MboI primer (5’-GTAGACTGCGTACCGATC-3’) incorporating an extra selective
nucleotide at its 3’-end (labeled with radioactive phosphorous-33) and ii) an MseI
primer (5’-GACGATGAGTCCTGAGTAA-3’) incorporating 2 extra selective
nucleotides at its 3’-end (both unlabelled). In total, 21 primer combinations were used
in the htAFLP analysis of the 48 M. catarrhalis isolates tested (Table 2). Analysis of
htAFLP gel fingerprints was performed using 1µl of each htAFLP reaction, which was
loaded onto a 5% denaturing polyacrylamide sequencing gel along with a radioactively-
labeled internal size marker. Fragments were separated by electrophoresis for 2 hours at
constant power (110 W). After electrophoresis, gels were fixed for 30 min in 10% acetic
acid, dried on glass plates and exposed to Fuji phosphor image plates for 16 hours.
Fingerprint patterns were visualized using a Fuji BAS-2000 phosphor image plate
scanner and the scanned images were analyzed using AFLP-QuantarPro software
(Keygene Products N.V.). Any fragment found to be present in 100% of M. catarrhalis
isolates (after exclusion of any ambiguous results) was discarded from the total set of
fragments generated and not therefore used for comparative analysis. Comparative
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phylogenetic analysis of the data was performed using two-dimensional hierarchical
clustering with a complete linkage algorithm and the Tanimoto similarity metric
(OmniVizR version 3.6 software; OmniViz Inc., USA). Similarity was based on the
number of positive attributes that two records have in common and the results were
ordered by dendrogram.
2.4. htAFLP polymorphic fragment sequencing
A PCR sequencing methodology was used to identify DNA sequences
associated with particular htAFLP polymorphic fragments. Essentially, a small piece of
the relevant polymorphic fragment was picked out of the htAFLP gel and added
directly to a PCR sequencing reaction mix containing the relevant htAFLP linker
primer. PCR sequencing was performed using dye terminators on an ABI 3700 capillary
sequencer. The sequence data from each polymorphic fragment was then compared to
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htAFLP linker primers
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numbers AX067426-AX067466 (comprising 41 contigs ranging in size from 429bp to
261,300bp in length), in order to identify homologous open reading frame (ORF)
sequences. The corresponding homologous ORF was then translated into protein and
the resultant protein sequence used to search publicly available protein sequence
databases to identify the nature of the original gene.
2.5. One-dimensional SDS-PAGE protein expression profiling
One-dimensional (1D) SDS-PAGE was performed using standard techniques,
with analysis being performed on all 48 M. catarrhalis isolates after growth under
identical conditions (overnight aerobic growth on Mueller Hinton agar at 37oC).
Differential protein markers were then identified by comparing the patterns of protein
expression between the complement resistant and complement sensitive isolates. A
differential protein expression marker was identified as a series of protein bands of
approximately the same molecular mass which were significantly associated with either
the complement resistant or complement sensitive phenotype (Fisher’s Exact Test
p<0.01). Once differential protein expression markers had been identified,
representative bands for each marker were picked from the 1D SDS-PAGE gel and
internal polypeptide fragment sequences identified using MALDI-TOF mass
spectrometry. These fragments were then compared to a translated (all 6 possible
reading frames) proteomic map of the unannotated M. catarrhalis genome (available at
GenBank accession numbers AX067426-AX067466), in order to identify the
component protein(s) present within each band/marker.
3. Results
3.1. Whole-cell genomic htAFLP analysis
In total, 41,364 fragments were obtained using 21 htAFLP primer
combinations on this set of 48 M. catarrhalis isolates, revealing the presence of 2,273
fragment length polymorphisms.  Comparative phylogenetic analysis of the data
indicated the presence of two distinct phylogenetic lineages, exhibiting approximately
5% difference in their branch depth (Fig. 1, Top). These two lineages were
differentiated by approximately 250 and 242 lineage-defining polymorphisms 
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Fig. 1. Phylogenetic analysis of a set of 48 M. catarrhalis isolates using htAFLP polymorphism data (Top),
and subsequent rearrangement into complement phenotype (Bottom). Vertical text = M. catarrhalis isolate
designations, where R = complement resistant, and S = complement sensitive phenotype. Light gray areas
represent the presence of a particular htAFLP polymorphism, whilst dark gray areas represent the absence
of a particular htAFLP polymorphism. Black areas represent regions where the presence or absence of
htAFLP polymorphic data could not be reliably determined. A and B = subpopulation associated
polymorphisms.
respectively (A and B in Fig. 1), with 40 (1.8%) of the htAFLP polymorphisms found
to be 100% specific for one or other of the two lineages identified. Additionally, there
was a significant correlation between complement phenotype and the two phylogenetic
lineages (Fisher’s exact test P = 0.016, Pearson r = 0.38 (0.10 – 0.60), P = 0.008).
Unfortunately however, no complement phenotype-specific htAFLP polymorphisms
were found (Fig. 1. Bottom), though 361 polymorphisms (16%) were found which were
statistically associated with complement phenotype, including 172 polymorphisms
associated with complement resistance and 189 with complement sensitivity (Fisher’s
exact test P < 0.05).
3.2 htAFLP polymorphic fragment sequencing
Using the results obtained from the htAFLP analysis, an arbitrary selection of
13 lineage-specific and 17 complement phenotype-associated polymorphic markers
were chosen and sequenced (Table 3). Of the lineage-specific markers, 11 mapped to
putative housekeeping genes, whilst 2 mapped to putative virulence associated genes.
The majority of the complement phenotype-associated markers were mapped to
housekeeping genes, though polymorphic marker F3121.511<N was found to reside
within the copB gene, a gene associated with iron acquisition [31], as well as being a
target for antibodies involved in pulmonary clearance [32] and being implicated in
altering serum resistance in vivo [24].
The sequence data for these htAFLP fragments are available from GenBank,
accession numbers AY771621 – AY771641 and AY944723 – AY944731.
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htAFLP Size                                            
Fragment              (bp)   Lineage    Putative gene description                        Predicted function of identified ORF     Accession number       
Table 3  
htAFLP polymorphic fragments associated with M. catarrhalis lineage and complement phenotype 
100% specific for genetic lineage
A / AC  F-134.585<N* 109 1 Probable carboxyl-terminal protease Protein metabolism AY771621
A / AC  F-379.208<N* 353      1 N-acetylglutamate synthase Protein metabolism AY771622
A / CA  F-166.034<N* 145 1 Phosphatase domain containing protein Unknown AY771623
A / CA  F-174.909<N* 151 1 Lipid A disaccharide synthase (lpxB) Biosynthesis of lipopolysaccharide AY771624
A / CA  F-177.244<N* 163 1 Elongation factor G Protein metabolism AY771625
A / CA  F-266.454<N* 245 1 DnaJ domain containing protein Molecular chaperone AY771626
A / GA  F-189.403<N* 160 1 Signal transduction histidine kinase  Signal transduction AY771629
A / GA  F-256.710<N* 228 1 Colicin tolerence gene (tolB)# Colicin A sensitivity/resistance AY771631
A / GA  F-375.414<N* 352 1 Ferredoxin-NADP+ reductase Protect against oxidative stress AY771632
A / TC  F-227.958<N* 201 1 Lipoprotein precursor (nlpD) Cell wall formation AY771634
A / AC  F-239.018<N** 217 2 Flavodoxin reductase Protects against oxygen radicals AY771638
A / CA  F-173.831<N** 144 2 Putative competence factor # Bacterial competence AY771639
A / CT  F-301.112<N** 280 2 Hypothetical protein Unknown AY771640
Associated with the complement resistant phenotype (P <0.05)
A / CA  F-315.261<N 287 Putative monooxygenase Energy production + conversion AY771627
A / GA  F-112.386<N 86 Mg-dependent DNase DNase AY771628
A / GA  F-217.923<N 135 Response regulator (gacA) Transcription/response regulator AY771630
A / CT  F-321.511<N 296 Major outer membrane protein CopB Iron acquisition / Serum resistance AY944723
A / TC  F-360.194<N 260 Adenylosuccinate synthetase Purine ribonucleotide synthesis AY771635
A / TC  F-217.777<N 193 Macrophage infectivity potentiator protein - Macrophage infection -
Acyl-coA dehydrogenase (intergenic) Energy production AY771633
T / TG  F-536.245<N 501 Homoserine dehydrogenase Protein metabolism AY944724
C / TA  F-194.337<N 163 16S rRNA processing protein (RimM) Maturation of 30S rRNA AY944725
C / TA  F-224.476<N 174 Membrane fusion protein -
Cation/multidrug efflux pump (intergenic) Membrane fusion / Efflux pump AY771636
G / TA  F-391.095<N 363 ParA ATPase Partitioning of bacterial plasmids AY771637
G / AT  F-191.261<N 121 Leucyl, phenylalanyl-tRNA-protein transferase Protein metabolism AY944726
Associated with the complement sensitive phenotype (P <0.05)
A / AC  F-316.046<N 289 Succinate-semi-aldehyde dehydrogenase Energy production + conversion AY944727
A / TC  F-318.602<N 303 Dihydrolipoamide acetyltransferase  Energy production + conversion AY771641
T / AG  F-168.547<N    142 Pyridoxamine 5-phosphate oxidase Co-enzyme metabolism AY944728
C / AT  F-214.578<N    189 Guanosine-3', 5- bis (diphosphate) Purine metabolism AY944729
G / AT  F-142.047<N    115 Replication helicase DNA unwinding AY944730
G / AT  F-310.917<N    285 Promoter for Acetaldehyde dehydrogenase II Energy production + conversion AY944731
* =  also associated with the complement resistant phenotype (P <0.05). ** =  also associated with the complement sensitive phenotype
(P <0.05). # = putative virulence gene
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3.3. 1D SDS-PAGE protein expression profiling
One-dimensional SDS-PAGE protein analysis of isolates grown under identical
conditions revealed six major protein expression markers significantly associated with
either the complement resistant or complement sensitive phenotype (Fisher’s Exact
Test p<0.01). These markers are shown in Fig. 2. MALDI-TOF mass spectrometric
analysis of representative bands from each of these protein expression markers
indicated the possible identities of the differentially expressed proteins associated with
each marker (Table 4). A simple PCR screening method indicated that at least one gene
(ompCD) was present in all 48 isolates tested despite its differential expression (data not
shown).
Table 4
Composition of 6 differential protein expression markers associated with
complement phenotype in 48 Moraxella catarrhalis isolates.
* / ** = significant at P <0.001 for complement resistant or complement sensitive phenotype
respectively. N.B. Protein markers E and F could not be distinguished by MALDI- TOF.
  Protein               Entrez
marker   Marker identity      accession no.
X** ATP-dependent helicase  / giI37526066IrefINP_929410
RNA polymerase Beta subunit / giI46914940IembICAG21715.1
DNA topoisomerase I giI33152456IrefINP_873809.1
A* Outer membrane haemagglutinin (Hag) giI22000942IgbIAAL78285.1
B* Omp CD precursor giI481874IpirIS39866
D** Hypothetical bacterial protein giI41690179IrefIZP_00146711
      E*/F** 28kDa outer membrane lipoprotein orgiI16272562IrefINP_438778.1
ABC-type metal transporter giI46133096IrefIZP_00156582.2
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Fig. 2. Representative one-dimensional SDS-PAGE gel showing differential protein expression markers
(labeled X, A, B,  D, E and F) obtained from 48 M. catarrhalis isolates grown overnight under identical
(nutrient replete) conditions. M = molecular weight marker in kDa.
4. Discussion
The expression of virulence traits within the M. catarrhalis species has previously
been associated with distinct sub-populations/lineages of isolates. Therefore, the
identification of lineage and/or virulence related markers would be a useful first step in
the development of a “universal” assay which could be used to distinguish between
isolates belonging to different M. catarrhalis lineages, and hence identify isolates
exhibiting an increased virulence potential. Such assays could be useful in the clinical
situation e.g. in influencing the decision over whether to use antibiotic therapy or not.
To achieve this aim, the most intensive analysis to date of a cohort of M.
catarrhalis isolates was performed, utilizing both whole-cell genomic polymorphism
analysis (high throughput AFLP), and one-dimensional protein expression profiling, to
identify possible “universal” lineage-specific and complement phenotype-associated
(virulence-associated) markers for this species. The wide potential of the AFLP
technique in the study of evolutionary / epidemiological aspects of taxonomy in general
[33,34], and bacterial taxonomy in particular [35-37], has already been established.
Indeed, the AFLP technique has several advantages over other genomic typing
techniques in that it may be applied to generate genetic fingerprints from organisms
without prior knowledge of genomic DNA sequences, and that mutations of only a
single base pair may be detected. In this study, an intensive high-throughput AFLP
strategy was utilized, revealing the presence of 40 lineage-specific genetic markers and
361 genetic markers significantly associated with the complement phenotype. The
subsequent identification of the genetic origin of a number of these markers, now
allows for a more targeted approach to be adopted (involving the testing of a larger
number of geographically diverse M. catarrhalis isolates), in order to determine the
“universal” nature of these lineage-specific and complement-associated markers within
this species. Further, the fact that most genetic markers were found to reside in putative
housekeeping genes, as opposed to genes under immune selection pressure, means that
they are likely to remain conserved within individual genetic lineages.
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One-dimensional SDS-PAGE gel electrophoresis of outer membrane protein
extracts has previously been used to compare M. catarrhalis isolates [38] and identify
possible vaccine candidates within this species [39,40]. However, the identification of
different protein expression markers between isolates exhibiting differential virulence
characteristics has been limited [41]. In this study, one-dimensional SDS-PAGE
analysis identified 6 major protein expression markers (within the approximately 50
possible protein markers visible upon each SDS-PAGE gel), which were significantly
associated with either the complement resistant or complement sensitive phenotype for
48 M. catarrhalis isolates. MALDI-TOF analysis indicated the component protein(s)
present within these 6 expression markers as including two virulence associated
proteins (a hemagglutinin [42,43] and an Omp CD precursor protein [44,45]). As with
the htAFLP results, these findings should be considered as forming the basis for a
more targeted protein expression profile approach, using a greater number of
geographically diverse M. catarrhalis isolates and possibly two-dimensional SDS-PAGE,
to further screen and validate our results. If such markers are to be used as potential
virulence markers, then the actual number of component proteins within each
individual differential protein expression marker is not as important as the
reproducibility of the marker per se. With respect to the mechanisms possibly
generating differential protein expression profiles, these may include: 1) the
presence/absence of a particular gene between isolates, 2) differences in gene or
promoter sequences which influence protein expression, 3) the lack of recognition of
promoter sequences in horizontally transmitted genes between isolates, 4) differential
receptor responses to identical growth conditions and 5) differential post-translational
processing. Indeed, both horizontal transmission and phase variable expression of
genes in M. catarrhalis have been described [46,47].
Finally, though the complement resistance phenotype is a virulence trait for M.
catarrhalis, complement resistance is not always a feature of isolates found within
virulence-associated clusters [12,13]. Also, though the uspA2 gene has been shown to
be involved in the expression of the complement resistant phenotype [20,21], it is not
the only mechanism currently associated with this phenotype and the presence of the
uspA2 gene does not necessarily lead to the expression of complement resistance per se
[13,20]. Therefore, assays that concentrate purely on the presence/absence of the uspA2
gene, or are based solely on the complement phenotype per se, may not accurately
indicate the true virulence potential of a particular M. catarrhalis isolate. By combining
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lineage-specific and complement phenotype-associated markers, the ability to
specifically identify virulent M. catarrhalis isolates should be increased.
 Acknowledgements
This work was supported by the Dutch Ministry of Economic Affairs (BTS
00145) and the SOPHIA Foundation for Medical Research, The Netherlands (Project:
397).
References
[1]   C. DiGiovanni, T.V. Riley, G.F. Hoyne, R. Yeo, P. Cooksey, Respiratory tract infections
due to Branhamella catarrhalis: epidemiological data from Western Australia, Epidemiol.
Infect. 99 (1987) 445-453.
[2]   H. Faden, Y. Harabuchi, J.J. Hong, Epidemiology of Moraxella catarrhalis in children during
the first 2 years of life: relationship to otitis media, J. Infect. Dis. 169 (1994) 1312-1317.
[3]   T. Kilpi, E. Herva, T. Kaijalainen, R. Syrjanen, A.K. Takala, Bacteriology of acute otitis
media in a cohort of Finnish children followed for the first two years of life, Pediatr.
Infect. Dis. J. 20 (2001) 654-662.
[4]   E.R. Wald, The microbiology of chronic sinusitis in children. A review, Acta
Otorhinolaryngol. Belg. 51 (1997) 51-54.
[5]   B.A. Claesson, M. Leinonen, Moraxella catarrhalis-an uncommon cause of community-
acquired pneumonia in Swedish children, Scand. J. Infect. Dis. 26 (1994) 399-402.
[6]   W.M. Abuhammour, N.M. Abdel-Haq, B.I. Asmar, A.S. Dajani, Moraxella catarrhalis
bacteremia: a 10-year experience, South. Med. J. 92 (1999) 1071-1074.
[7]   K. Prellner, P. Christensen, B. Hovelius, C. Rosen, Nasopharyngeal carriage of bacteria in
otitis-prone and non-otitis-prone children in day-care centres, Acta Otolaryngol. 98
(1984) 343-350.
[8]   J.P. Hays, K. Eadie, C.M. Verduin, J. Hazelzet, H. Verbrugh, A. van Belkum, Changes in
genetic types and population dynamics of Moraxella catarrhalis in hospitalized children are
not associated with an exacerbation of existing disease, J. Med. Microbiol. 52 (2003) 815-
820.
Chapter 5.                                                                                                          Whole-cell genomic analysis
82
[9]   D. Lieberman, M. Ben-Yaakov, Z. Lazarovich, S. Hoffman, B. Ohana, M.G. Friedman, B.
Dvoskin, M. Leinonen, I. Boldur, Infectious etiologies in acute exacerbation of COPD,
Diagn. Microbiol. Infect. Dis. 40 (2001) 95-102.
[10]   S. Sethi, N. Evans, B.J. Grant, T.F. Murphy, New strains of bacteria and exacerbations of
chronic obstructive pulmonary disease, N. Engl. J. Med. 347 (2002) 465-471.
[11]   W.S. Lim, J.T. Macfarlane, T.C. Boswell, T.G. Harrison, D. Rose, M. Leinonen, P. Saikku,
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to
hospital: implications for management guidelines, Thorax. 56 (2001) 296-301.
[12]   C.M. Verduin, M. Kools-Sijmons, J. van der Plas, J. Vlooswijk, M. Tromp, H. van Dijk, J.
Banks, H. Verbrugh, A. van Belkum, Complement-resistant Moraxella catarrhalis forms a
genetically distinct lineage within the species, FEMS Microbiol. Lett. 184 (2000) 1-8.
[13]   H.J. Bootsma, H.G. van der Heide, S. van de Pas, L.M. Schouls, F.R. Mooi, Analysis of
Moraxella catarrhalis by DNA typing: evidence for a distinct subpopulation associated with
virulence traits, J. Infect. Dis. 181 (2000) 1376-1387.
[14]   F.J. Schmitz, A. Beeck, M. Perdikouli, M. Boos, S. Mayer, S. Scheuring, K. Kohrer, J.
Verhoef, A.C. Fluit, Production of BRO beta-lactamases and resistance to complement
in European Moraxella catarrhalis isolates, J. Clin. Microbiol. 40 (2002) 1546-1548.
[15]   C. Hol, C.M. Verduin, E.E. Van Dijke, J. Verhoef, A. Fleer, H. van Dijk, Complement
resistance is a virulence factor of Branhamella (Moraxella) catarrhalis, FEMS Immunol.
Med. Microbiol. 11 (1995) 207-211.
[16]   B. Wolf, M. Kools-Sijmons, C. Verduin, L.C. Rey, A. Gama, J. Roord, J. Verhoef, A. van
Belkum, Genetic diversity among strains of Moraxella catarrhalis cultured from the
nasopharynx of young and healthy Brazilian, Angolan and Dutch children, Eur. J. Clin.
Microbiol. Infect. Dis. 19 (2000) 759-764.
[17]   M.C. Enright, H. McKenzie, Moraxella (Branhamella) catarrhalis-clinical and molecular
aspects of a rediscovered pathogen, J. Med. Microbiol. 46 (1997) 360-371.
[18]   C. Hol, C.M. Verduin, E. van Dijke, J. Verhoef, H. van Dijk, Complement resistance in
Branhamella (Moraxella) catarrhalis, Lancet. 341 (1993) 1281.
[19]   T. Nordstrom, A.M. Blom, A. Forsgren, K. Riesbeck, The emerging pathogen Moraxella
catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous
surface proteins A1 and A2, J. Immunol. 173 (2004) 4598-4606.
[20]   A.S. Attia, E.R. Lafontaine, J.L. Latimer, C. Aebi, G.A. Syrogiannopoulos, E.J. Hansen,
The UspA2 protein of Moraxella catarrhalis is directly involved in the expression of serum
resistance, Infect. Immun. 73 (2005) 2400-2410.
[21]   C.M. Verduin, M. Jansze, J. Verhoef, A. Fleer, H. van Dijk, Complement resistance in
Moraxella (Branhamella) catarrhalis is mediated by a vitronectin-binding surface protein.,
Clin. Exp. Immunol. 97 (1994) 50.
Chapter 5.                                                                                                          Whole-cell genomic analysis
83
[22]   C. Aebi, E.R. Lafontaine, L.D. Cope, J.L. Latimer, S.L. Lumbley, G.H. McCracken, Jr.,
E.J. Hansen, Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella
catarrhalis 035E, Infect. Immun. 66 (1998) 3113-3119.
[23]   J.C. McMichael, M.J. Fiske, R.A. Fredenburg, D.N. Chakravarti, K.R. VanDerMeid, V.
Barniak, J. Caplan, E. Bortell, S. Baker, R. Arumugham, D. Chen, Isolation and
characterization of two proteins from Moraxella catarrhalis that bear a common epitope,
Infect. Immun. 66 (1998) 4374-4381.
[24]   M.E. Helminen, I. Maciver, M. Paris, J.L. Latimer, S.L. Lumbley, L.D. Cope, G.H.
McCracken, Jr., E.J. Hansen, A mutation affecting expression of a major outer
membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo, J.
Infect. Dis. 168 (1993) 1194-1201.
[25]   C. Aebi, B. Stone, M. Beucher, L.D. Cope, I. Maciver, S.E. Thomas, G.H. McCracken, Jr.,
P.F. Sparling, E.J. Hansen, Expression of the CopB outer membrane protein by
Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and
lactoferrin, Infect. Immun. 64 (1996) 2024-2030.
[26]   T.F. Murphy, A.L. Brauer, N. Yuskiw, T.J. Hiltke, Antigenic structure of outer membrane
protein E of Moraxella catarrhalis and construction and characterization of mutants,
Infect. Immun. 68 (2000) 6250-6256.
[27]   A. Zaleski, N.K. Scheffler, P. Densen, F.K. Lee, A.A. Campagnari, B.W. Gibson, M.A.
Apicella, Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of Moraxella
catarrhalis is a factor in resistance to bactericidal activity mediated by normal human
serum, Infect. Immun. 68 (2000) 5261-5268.
[28]   K. Furano, A.A. Campagnari, Inactivation of the Moraxella catarrhalis 7169 ferric uptake
regulator increases susceptibility to the bactericidal activity of normal human sera, Infect.
Immun. 71 (2003) 1843-1848.
[29]   C.M. Verduin, C. Hol, E. Van Dijke, J.A. Faber, M. Jansze, J. Verhoef, H. Van Dijk,
Assessment of complement-mediated killing of Moraxella (Branhamella) catarrhalis isolates
by a simple method, Clin. Diagn. Lab. Immunol. 2 (1995) 365-368.
[30]   P. Vos, R. Hogers, M. Bleeker, M. Reijans, T. van de Lee, M. Hornes, A. Frijters, J. Pot, J.
Peleman, M. Kuiper, et al., AFLP: a new technique for DNA fingerprinting, Nucleic
Acids Res. 23 (1995) 4407-4414.
[31]   R.A. Bonnah, R.H. Yu, H. Wong, A.B. Schryvers, Biochemical and immunological
properties of lactoferrin binding proteins from Moraxella (Branhamella) catarrhalis, Microb.
Pathog. 24 (1998) 89-100.
[32]   M.E. Helminen, I. Maciver, J.L. Latimer, L.D. Cope, G.H. McCracken, Jr., E.J. Hansen, A
major outer membrane protein of Moraxella catarrhalis is a target for antibodies that
enhance pulmonary clearance of the pathogen in an animal model, Infect. Immun. 61
(1993) 2003-2010.
Chapter 5.                                                                                                          Whole-cell genomic analysis
84
[33]   K.J. Kochan, D.A. Wright, L.J. Schroeder, J. Shen, D.C. Morizot, Genetic linkage maps of
the West African clawed frog Xenopus tropicalis, Dev Dyn. 226 (2003) 99-102.
[34]   F.J. Massawe, M. Dickinson, J.A. Roberts, S.N. Azam-Ali, Genetic diversity in bambara
groundnut (Vigna subterranea (L.) Verdc) landraces revealed by AFLP markers, Genome.
45 (2002) 1175-1180.
[35]   P. Janssen, R. Coopman, G. Huys, J. Swings, M. Bleeker, P. Vos, M. Zabeau, K. Kersters,
Evaluation of the DNA fingerprinting method AFLP as an new tool in bacterial
taxonomy, Microbiology. 142 (1996) 1881-1893.
[36]   J.R. Gibson, E. Slater, J. Xerry, D.S. Tompkins, R.J. Owen, Use of an amplified-fragment
length polymorphism technique to fingerprint and differentiate isolates of Helicobacter
pylori, J. Clin. Microbiol. 36 (1998) 2580-2585.
[37]   H.J. Aarts, L.A. van Lith, J. Keijer, High-resolution genotyping of Salmonella strains by
AFLP-fingerprinting, Lett. Appl. Microbiol. 26 (1998) 131-135.
[38]   L.C. Bartos, T.F. Murphy, Comparison of the outer membrane proteins of 50 strains of
Branhamella catarrhalis, J. Infect. Dis. 158 (1988) 761-765.
[39]   M.E. Helminen, I. Maciver, J.L. Latimer, J. Klesney-Tait, L.D. Cope, M. Paris, G.H.
McCracken, Jr., E.J. Hansen, A large, antigenically conserved protein on the surface of
Moraxella catarrhalis is a target for protective antibodies, J. Infect. Dis. 170 (1994) 867-
872.
[40]   K.L. Klingman, T.F. Murphy, Purification and characterization of a high-molecular-weight
outer membrane protein of Moraxella (Branhamella) catarrhalis, Infect. Immun. 62 (1994)
1150-1155.
[41]   H. McKenzie, M.G. Morgan, J.Z. Jordens, M.C. Enright, M. Bain, Characterisation of
hospital isolates of Moraxella (Branhamella) catarrhalis by SDS-PAGE of whole-cell
proteins, immunoblotting and restriction-endonuclease analysis, J. Med. Microbiol. 37
(1992) 70-76.
[42]   M.M. Holm, S.L. Vanlerberg, D.D. Sledjeski, E.R. Lafontaine, The Hag protein of
Moraxella catarrhalis strain O35E is associated with adherence to human lung and middle
ear cells, Infect. Immun. 71 (2003) 4977-4984.
[43]   M.M. Pearson, E.R. Lafontaine, N.J. Wagner, J.W. St Geme, 3rd, E.J. Hansen, A hag
mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination,
autoagglutination, and immunoglobulin D-binding activities, Infect. Immun. 70 (2002)
4523-4533.
[44]   M.M. Holm, S.L. Vanlerberg, I.M. Foley, D.D. Sledjeski, E.R. Lafontaine, The Moraxella
catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells,
Infect. Immun. 72 (2004) 1906-1913.
Chapter 5.                                                                                                          Whole-cell genomic analysis
85
[45]   T.F. Murphy, J.M. Kyd, A. John, C. Kirkham, A.W. Cripps, Enhancement of pulmonary
clearance of Moraxella (Branhamella) catarrhalis following immunization with outer
membrane protein CD in a mouse model, J. Infect. Dis. 178 (1998) 1667-1675.
[46]   E.R. Lafontaine, N.J. Wagner, E.J. Hansen, Expression of the Moraxella catarrhalis UspA1
protein undergoes phase variation and is regulated at the transcriptional level, J.
Bacteriol. 183 (2001) 1540-1551.
[47]   A. Mollenkvist, T. Nordstrom, C. Hallden, J.J. Christensen, A. Forsgren, K. Riesbeck, The
Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences




         Chapter 6
Total genome polymorphism and low frequency of intra-genomic
variation in the uspA1 and uspA2 genes of Moraxella catarrhalis
 in otitis prone and non-prone children up to 2 years of age.
Consequences for vaccine design?
John P Hays, Cindy van der Schee, Anita Loogman, Kim Eadie, Cees Verduin,
Howard Faden, Henri Verbrugh, Alex van Belkum.
Vaccine  2003; 21(11-12): 1118 - 1124
Chapter 6.                                                                                                          Total genome polymorphism
88
ABSTRACT
Intra-genomic variation in the uspA1 and uspA2 genes of Moraxella catarrhalis
was studied using pulsed field gel electrophoresis (PFGE) and polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. From a set of
91 Moraxella catarrhalis isolates, 19 pairs of PFGE identical isolates were found. 5 pairs
originated from otitis non-prone children, 11 pairs from otitis prone children and for 3
pairs, one of the pair originated from an otitis prone and the other from an otitis non-
prone child. No particular M. catarrhalis isolate was associated with either the otitis
prone or non-prone children. 1 of these 19 pairs of isolates was found to exhibit both
uspA1 and uspA2 intra-genomic variation, whilst another pair exhibited uspA2 intra-
genomic variation only. Sequence data obtained from these variants showed that PCR-
RFLP pattern differences reflected actual changes in predicted amino-acid composition
and that  minor amino-acid changes in a 23 base pair “NINNIY” repeat region (a
conserved UspA1 and UspA2 binding site for the neutralizing antibody mAb17C7)
occurred. Variation in the uspA2 5’ non-coding “AGAT” repeat region was also
observed. These results may have implications for future M. catarrhalis vaccines
comprising UspA1 or UspA2 components.
1.  Introduction
Moraxella catarrhalis is a common commensal of the human upper respiratory tract,
which has been associated with a number of disease states [1-3]. The organism has been
found to be the third most common cause of acute otitis media in children [4,5] and
has also been implicated in chronic otitis media [6]. In adults, M. catarrhalis has been
associated with both acute and chronic bronchitis [7,8].
The outer membrane proteins of M. catarrhalis express major antigenic determinants [9],
with different isolates apparently sharing similar protein profiles [10]. Two important
examples of these outer membrane proteins are the ubiquitous surface proteins A1 and
A2 (UspA1 and UspA2) which share similar overall morphology (comprising an N-
terminal head, a left-handed coiled coil segment and a C-terminal membrane anchor
region [11]) as well as several conserved amino acid repeat motifs (often present in
multiple copies) [12,13]. The UspA1 protein appears to play a role in cellular
attachment [13,14], whilst the UspA2 protein appears to be mainly involved in
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complement resistance [15]. Most infants have maternally derived serum IgG antibodies
to these UspA1 and UspA2 proteins at 2 months of age and adults have significantly
higher IgG titers than children. Antibodies to UspA1 and UspA2 cross-react and are
associated with bactericidal activity [16] and both UspA1 and UspA2 are currently
being considered as possible vaccine candidates for M. catarrhalis [17]. Indeed, a recent
publication has indicated that a common epitope to mAb17C7 (a murine M. catarrhalis
bactericidal IgG1 antibody [18]) was present in 97% of M. catarrhalis isolates from young
children. [19].
In this study, a set of 91 previously characterized M. catarrhalis isolates (obtained from
children followed longitudinally up to 2 years of age) were investigated using pulsed-
field gel electrophoresis (PFGE), PCR - restriction fragment length polymorphism
(PCR-RFLP) and PCR sequencing, in order to determine the presence or absence of
uspA1 and/or uspA2 intra-genomic variation. In order to further assess uspA1 and
uspA2 polymorphisms, changes in the “NINNIY” repeat sequence by partial
sequencing of the uspA1 genes and variations in the “AGAT” 5’ non-coding repeat
region of the uspA2 genes were investigated for intra-genomic variants. Complement
resistance phenotypes for all specimens were also obtained.
2.  Materials and Methods
2.1. Bacterial isolates.
The bacterial isolates comprised 91 M. catarrhalis isolates longitudinally
collected from 18 different children in the first 2 years of life [4]. Nasopharyngeal swabs
were taken at 1-6, 8, 10, 12, 15, 18, 21 and 24 months, with tympanometry and
pneumatic otoscopy also being performed. M. catarrhalis isolates were classified using
the initials of the patient followed by a sequential number (dependant on whether the
isolate was the first, second, third etc isolate from that particular child).
2.2. Pulsed field gel electrophoresis (PFGE).
Pulsed field gel electrophoresis was performed as detailed by Verduin et al [20].
PFGE patterns were analyzed using GelCompar software (Applied Maths, Gent,
Belgium). For the definition of sub-types, up to three small band-size differences were
tolerated when compared to the reference pattern.
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2.3. UspA1 and uspA2 PCR-RFLP.
uspA1 and uspA2 genes were PCR amplified using standard techniques from
isolates exhibiting identical PFGE patterns using primer pairs USPA1t1/USPA1t2 and
USPA2t1/USPA2 [13] respectively (both primer pairs include non-coding regions).
After PCR amplification, restriction digestion of 15µl of PCR product was performed
using 10U of Hae III or 10U of Alu I (New England Biolabs Inc., MA, USA) according
to the manufacturer’s instructions. The uspA1 and uspA2 genes from isolates with
identical PFGE patterns but variant PCR-RFLP patterns were re-amplified using
primer pairs uspA1start/RTB1-8 and P8959/RTB2-10 respectively (genomic primers)
and re-digested with Alu I and Hae III. Primer details are shown in Figure 1.
Figure 1. Schematic representation of the positions of uspA1 and uspA2 PCR and sequencing primers. * =
sequencing primer used for “NINNIY” repeat. # = Primer sequences obtained from Aebi et al, [13]. ## =
Primer sequences obtained from Stutzmann Meier et al, [19]. atg = start codon. -35, -10 = RNA
polymerase binding sites. Poly G tract / poly AGAT tract = short sequence repeats.
U S P A 1 /5  5 ’ T C A T T G G C T T G T G C T T T G 3 ’
U S P A 1 s t a r t   5 ’ A A A G T G A A G A A A A A T G C C G C 3 ’
U s p A 1
U S P A 1 t1 # U S P A 1 / s t a r t
U S P A 1 /5 * U S P A 1 t2 #a t g
5 ’ 3 ’
s t o p
p o ly  G  t r a c t
- 3 5    - 1 0
••
U S P A 2 t2  5 ’ G G A T C C C G C T G T A T G C C G C T A C T C G C A G C T 3 ’
P 8 9 5 9  5 ’ T C G C T G T A A C C A G T G C C A 3 ’
U S P A 1 t2  5 ’ T T T T G C T C A G C G T C A T G G 3 ’
U S P A 1 t1  5 ’ T G T G A G C A A A T G A C T G G C 3 ’
5 ’ G G C T C T C T G C C A A T C A G T A C A C T A C 3 ’U S P A 2 t1
U s p A 2
U S P A 2 t1 # P 8 9 5 9
U S P A 2  t2 #a t g
5 ’ 3 ’
s t o p
p o ly  A G A T  t r a c t
- 3 5     - 1 0
••
R T B 2 - 1 0 # #
R T B 1 - 8 # #
R T B 2 - 1 0  5 ’ T T G A G C C A T A G C C A C C A A G T G C 3 ’
R T B 1 - 8  5 ’ G C A T C T G A C C A G C T T A G A C C A A T C 3 ’
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2.4. UspA1 and uspA2 sequencing reactions.
In order to study variation in the “NINNIY” repeat sequence (a conserved
UspA1 and UspA2 epitope recognized by monoclonal antibody mAb17C7); partial
sequencing of the uspA1 gene of intra-genomic variants 3JB-2, 4LK-2, 16CK-2 and
16CK-3 was performed using primer USPA1/5. The uspA2 5’ non-coding “AGAT”
repeat regions of these intra-genomic variants were also compared using sequence data
derived from primer USPA2t1 (see Fig. 1. for primer sequences).
2.5. Complement resistance assay.
Complement resistance was determined using the “culture and spot” method
[21,22]. Basically, 100 µl of a 1.5 x 108 suspension of M. catarrhalis was spread on a
blood agar plate and allowed to dry. Next, 50 µl of 50% human pooled serum and 50 µl
of heat treated (56oC for 30 minutes) 50% human pooled serum was spotted onto the
lawn of bacteria and the plates incubated at 37oC overnight. The phenotype of the
isolate was then determined. Complement resistant, intermediate and sensitive
phenotypes were graded as follows (i.e. ≤ 50 colonies = sensitive; normal growth =
resistant; > 50 colonies = intermediate).
3.  Results
3.1. Pulsed field gel electrophoresis (PFGE).
 62 different PFGE band patterns were observed in this particular set of 91 M.
catarrhalis isolates (Fig. 2.), with 19 identical patterns attributable to 2 or more M.
catarrhalis isolates. Of these 19 pairs of identical isolates, 5 pairs originated from otitis
non-prone children (e.g. isolates MG2-1 and MG2-2), 11 pairs from otitis prone
children (e.g. isolates EE11-3 and EE11-4), and 3 pairs where one isolate originated
from otitis prone and the other isolate from otitis non-prone children (e.g. isolates
CA9-3 and BW18-6). No particular PFGE pattern was associated with either otitis
prone or otitis non-prone children. At least one major change in PFGE pattern was
observed in every child with three or more M. catarrhalis culture positive specimens. The
dendrogram obtained for this set of M. catarrhalis isolates indicated a division into two
major clusters. In one cluster, the two complement sensitive and four complement
intermediate isolates were grouped, whilst in the other cluster, the remaining sixty eight
complement resistant and seventeen intermediate isolates were found.
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Figure 2. Dendrogram showing the relatedness of Moraxella catarrhalis isolates on the basis of PFGE
patterns. Band tolerance was set at 1.5% with bands normalized against reference isolate CK16-7†. Bold
type = comparable PFGE patterns. * = uspA1 and/or uspA2 intra-genomic variants. S = complement
sensitive, I = intermediate resistant, R = resistant. Children MP7, ZK8, CA9, AR10, EE11, SP12, DH13,
TS14 and JW15 were otitis prone.
3.2. UspA1 and uspA2 PCR-RFLP.
UspA1 and/or uspA2 intra-genomic variation (different uspA1 and/or uspA2
PCR-RFLP types in isolates exhibiting the same PFGE pattern) was observed in 2 pairs
or 4% (4/91) of M. catarrhalis isolates (Figs. 2. and 3.), infecting 17% (3/18) of the
children followed (children 3JB, 4LK and 16CK). Intra-genomic variation was observed
using both gene-only encoding primer pairs as well as for primers which also amplified
portions of the 5’ and 3’ non-coding regions. Both pairs of intra-genomic isolates
originated from otitis non-prone children, with 1 pair (3JB-2 and 4LK-2) exhibiting
both uspA1 and uspA2 intra-genomic variation and the other pair (16CK-2 and 16CK-
3) exhibiting uspA2 intra-genomic variation only (Fig. 3.)
Figure. 3. Intra-genomic variation in M. catarrhalis, as determined by pulsed field gel electrophoresis
(PFGE) pattern similarity after Spe I digestion of genomic DNA (Gel 1.) and subsequent PCR-RFLP
analysis of uspA1 and uspA2 genes using Hae III (Gel 2.). PFGE patterns (Gel 1) : lane 1 = lambda ladder,
lane 2 = 16CK-2, lane 3 = 16CK-3, lane 4 = lambda ladder, lane 5 = 3JB-2 and lane 6 = 4LK-2. PCR-
RFLP patterns (Gel 2): lane 1= 600bp molecular weight marker, lane 2 = 16CK-2 uspA1, lane 3 = 16CK-3
uspA1, lane 4 = 3JK-2 uspA1, lane 5 = 4LK-2 uspA1, lane 6 = 16CK-2 uspA2 and lane 7 = 16CK-3 uspA2.
Gel 1.
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3.3 UspA1 and uspA2 sequencing.
Partial uspA1 gene sequencing and translation revealed that the “NINNIY”
epitope within these intra-genomic variants contained only minor amino-acid changes
(Fig. 4.). Moreover, comparison of the sequenced regions against the previously
published UspA1 sequences for M. catarrhalis isolates O35E, O12E and O46E indicated
that the partial UspA1 amino-acid sequence of isolate 4LK-2 had some homology to
the previously published isolate O46E UspA1. In contrast, this same intra-genomic
variant isolate, when isolated from child 3JB, showed homology to the previously
published isolate O35E. Comparisons of the uspA2 5’ non-coding regions also
indicated polymorphism, in that the number of “AGAT” repeats was highly variable
(data not shown), with 11 “AGAT” repeats for isolate 16CK-2, 14 for isolate 16CK-3
and 20 for isolate 4LK-2.  The “AGAT” repeat sequence was absent in the intra-
genomic variant isolated from child 3JB (3JB-2), this absence being explained by
homology to the previously published TTA37 uspA2H hybrid sequence (which
combines a N-terminal half UspA1 protein with a C-terminal half UspA2 protein and
therefore does not contain a 5’ non-coding  “AGAT” repeat sequence) [15].
Figure. 4. Translated UspA1 gene sequence alignments (MegAlign 4.0 ©, DNASTAR Inc., Madison, USA)
obtained using duplicate USPA1/5 primer sequencing reactions. * = Partial UspA1amino-acid sequences
obtained from the National Library of Medicine “PubMed” website
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi).  Bold = “NINNIY” conserved repeat sequence to
which neutralizing antibody Mab17C7 binds. Underlined = amino acid changes in “NINNIY” sequence.
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A K N Q A D I Q - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - T L E N N V G E E  
6 0 7 0 8 0 9 0 1 0 0 1 1 0
L L N L S G R L I D Q K A D I D N N I N H I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L N L S G R L L D Q K A D I D N N I N N I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L N L S G R L L D Q K A D I D N N I N H I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L N L S G R L L D Q K A D I D N N I N H I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L N L S G R L I D Q K A D I D N N I N N I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L D L S G R L L D Q K A D I D N N I N N I Y E L A Q Q Q D Q H S S D I K T L K N N V E E G L L D L S G R L I D Q K A D  
L L N L S G R L L D Q K A D I D N N I N N I Y D L A Q Q Q D Q H S S D I K T L K K N V E E G L L D L S G R L I D Q K A D  
1 2 0
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - I A K                              
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - I A K                              
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - I A K                              
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - I A K                              
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - L T K                              
L T K D I K T L K N N V E E G L L D L S G R L I D Q K A D I A K                              
L T K D I K T L E N N V E E G L L D L S G R L I D Q K A D I A K                              
O 1 2 E *
O 3 5 E *
1 6 C K - 2
1 6 C K - 3
3 J B - 2
4 L K - 2
O 4 6 E *
O 1 2 E *
O 3 5 E *
1 6 C K - 2
1 6 C K - 3
3 J B - 2
4 L K - 2
O 4 6 E *
O 1 2 E *
O 3 5 E *
1 6 C K - 2
1 6 C K - 3
3 J B - 2
4 L K - 2
O 4 6 E *
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3.4. Complement resistance assay.
 75% of isolates (68/91) were found to be fully complement resistant, 23%
(21/91) complement intermediate resistant and 2% (2/91) complement sensitive. 43%
(9/21) of the complement intermediate isolates were isolated from otitis prone children
compared to 59% (40/68) of the complement resistant isolates (Fig. 2.).
4.  Discussion
A high degree of isolate variability within M. catarrhalis isolates has previously been
reported [20,23-26]. However, the finding of low frequency intra-genomic variation in
the uspA1 and/or uspA2 genes of 4% of isolates within this study adds further to the
extent of genomic variation present within this species.
The distribution of PFGE patterns within this set of isolates appeared to be random in
nature, with no particular PFGE pattern being associated with the otitis prone or otitis
non-prone children. This random distribution of PFGE patterns was also observed for
“first acquisition” isolates within the two groups. These observations indicate that re-
colonization and re-infection was a frequent event in this cohort of children and that
genetic factors within otitis prone children themselves probably predisposes them to
repeated M. catarrhalis infection, as opposed to pathogenic factors associated with any
particular M .catarrhalis isolate per se.
Despite the random distribution of PFGE patterns between otitis prone and non-prone
children, two distinct clusters of PFGE patterns could be observed, namely between
complement sensitive and complement resistant isolates. Moreover, though only two
complement sensitive isolates were found within this set of isolates, these results (when
added to those previously published by [27] and [20]), further the suggestion of
clonality in complement resistant M. catarrhalis isolates [28]. It therefore appears that
complement resistant M. catarrhalis isolates either originated more recently than
complement sensitive isolates or perhaps, that the complement resistance phenotype in
some way constrains genetic diversity within this species.
Complement resistance in M. catarrhalis has been previously associated with disease
causing isolates [29]. In relation to other studies [19,29-33], the percentage of
complement resistant isolates from this set of USA isolates (98%) was high. This could
be attributable to the young age of the patients from which the isolates were cultured.
During the first two years of life, infants have relatively naïve immune systems and are
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likely to come into contact with many novel infectious agents possibly leading to more
frequent activation of the complement system in this age group. In this scenario it is
likely that complement resistant M. catarrhalis isolates would have a distinct advantage in
establishing infection.
The UspA1 and UspA2 proteins have been put forward as possible vaccine
candidates [19,34,35,36,37], with encouraging results being published regarding UspA
immunized mice [17,38], as well as passive immunization with UspA reactive antibody
[18]. Indeed, previous research has indicated that conserved identical repeat regions
within both the UspA1 and UspA2 proteins could contain important neutralizing
epitopes (e.g. the “NINNIY” repeat and monoclonal antibody mAb17C7
[12,13,18,19,35]). Interestingly, partial uspA1 gene sequencing results for the
“NINNIY” repeat sequence in the intra-genomic variants found within this set of
isolates, indicated that displacement of this region could occur in identical isolates (3JB-
2 and 4LK-2). However, it should be noted that alignment of these “NINNIY”
sequences with previously published UspA1 protein sequences, indicated that 3JB-2
and 4LK-2 UspA1 proteins were related to two different isolates (O35E and O46E
respectively). This raises the possibility that either uspA1 (partial) gene transfer occurs
between identical isolates, or that PFGE is not a reliable method for the determination
of isolate identities in M. catarrhalis.
Variation in the uspA2 5’ non-coding “AGAT” repeat sequence may possibly
be linked to phase variation in expression of the UspA2 protein, in that variation in a
poly “G” tract region (occupying an analogous position in the 5’ non-coding region of
the M. catarrhalis uspA1 gene) has previously been linked to variation in expression of
the uspA1 gene [39]. Such phase variable expression of the uspA2 gene could be
important as a survival mechanism for M. catarrhalis. In this scenario, the up-regulation
of UspA2 expression would be advantageous in complement rich environments, whilst
down-regulation would be advantageous against an immune response which has
generated a particularly effective UspA2 bactericidal antibody.  However, further work
is required in order to confirm or refute this theory.
This is the first report of intra-genomic variation within the M. catarrhalis uspA1 and
uspA2 genes. These results indicate that diversity within the M. catarrhalis species is
greater than originally reported, (though occurring at a relatively low frequency), and
that minor changes in conserved epitopes may occur in identical strains. Previously
published reports have indicated that the presence of these conserved epitopes within
the UspA1 and UspA2 proteins could be useful in the design of a future M. catarrhalis
Chapter 6.                                                                                                          Total genome polymorphism
97
vaccine. However, two important questions remain to be answered about the potency
of these conserved epitopes with respect to human disease. Firstly, why do repeat M.
catarrhalis infections and/or re-infections occur if conserved epitopes act as sites for the
production of bactericidal antibody? Secondly, if conserved epitopes provide protection
against the host immune system, what process is driving M. catarrhalis variation and
uspA1 / uspA2 intra-genomic variation? Maybe the mouse model (on which previous
neutralizing antibody studies have been based) does not accurately represent in vivo M.
catarrhalis infection in humans.
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ABSTRACT
Moraxella catarrhalis is a common commensal of the human respiratory tract,
which has been associated with a number of disease states, including acute otitis media
in children and exacerbations of chronic obstructive pulmonary disease in adults.
During studies to investigate the outer membrane proteins of this bacterium, two novel
major proteins of approximately 19kDa and 16kDa (named OMP J1 and OMP J2
respectively) were identified. Further analysis indicated that these two proteins
possessed almost identical gene sequences apart from two insertion/deletion events in
predicted external loops present within the putative barrel-like structure of the proteins.
Development of a PCR screening strategy found a 100% (96/96) incidence for the gene
encoding the OMP J1 and OMP J2 proteins within a set of geographically diverse M.
catarrhalis isolates, as well as a significant association of OMP J1 / OMP J2 with both
genetic lineage and complement phenotype (Fisher’s Exact Test P <0.01). Experiments
using two ∆ompJ2 mutants (one complement resistant and the other complement
sensitive), indicated that both were less easily cleared from the lungs of mice compared
to their isogenic wild-type counterparts, with a significant difference in bacterial
clearance being observed for the complement resistant isolate but not its isogenic
∆ompJ2 mutant (unpaired Student’s t-test P <0.001 and P = 0.32).  In this publication,
the authors characterize a novel outer membrane protein of Moraxella catarrhalis which
exists in two variant forms associated with particular genetic lineages, and which are
suggested to contribute to bacterial clearance from the lungs.
INTRODUCTION
The Gram-negative bacterium Moraxella catarrhalis is a common commensal of the
human upper respiratory tract which has been associated with a number of disease
states, including acute otitis media in children (9, 14) and both acute and chronic
bronchitis in adults (16, 32). Nosocomial outbreaks of this pathogen have also been
reported (10, 34), as well as cases of near fatal pneumonia (11). The morbidity burden
of M. catarrhalis is particularly noticeable in young children suffering from recurrent
otitis media episodes (13) and in adults presenting with chronic obstructive pulmonary
disease (COPD) (35).
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One particularly important virulence trait of M. catarrhalis is serum resistance (21),
with several outer membrane proteins (OMPs) being implicated in the expression of
this particular phenotype. Of particular importance is the UspA2 protein, a vitronectin
binding protein whose N-terminal half may confer complement resistance in certain
isolates (1, 33, 41). Other OMPs associated with virulence include the iron acquisition
protein CopB (20), a hemagglutinin (28), and the lipooligosaccharide (44). Interestingly,
there is increasing evidence to suggest that particular virulence traits are associated with
distinct sub-populations of M. catarrhalis (8, 12, 42).
Several OMPs of M. catarrhalis have been shown to elicit an antibody response in
humans and have therefore been suggested as potential vaccine candidates, these
include the immunoglobulin D-binding protein (MID) (15), and the major heat-
modifiable protein Omp CD (31, 43). However, an ideal vaccine candidate has not yet
been described.
In this article, a novel outer membrane protein of M. catarrhalis that exists in two
major forms (OMP J1 and OMP J2) is described and characterized. Sequence variation
of the two forms and their relationship with both genetic lineage and complement
phenotype are discussed. Preliminary investigations into the role of the protein were
performed by comparing the clearance of two OMP J2 knockout (∆ompJ2) mutants
against their isogenic wild-type counterparts in a mouse pulmonary model of infection
MATERIALS AND METHODS
Bacterial isolates. In total, a group of 96 M. catarrhalis isolates were utilized in this
study, comprising 35 isolates from The Netherlands (1989 – 1997), 6 from Ghana
(1995), and 55 from the USA (1991 – 1994, kindly supplied by Dr. H. Faden,
Department of Pediatrics, Children’s Hospital of Buffalo, New York). All of the
isolates were cultured from children on Columbia blood agar, apart from 6 of the
Dutch isolates, which were cultured from adults.
Identification of OMP J. One-dimensional SDS-PAGE analysis was performed
using standard techniques with 100µg protein loaded per gel lane. Membrane fractions
of M. catarrhalis were isolated by ultrasonic treatment and extraction in 1% sarcosyl
according to the methodology previously described by Klingman and Murphy (24).
Tandem mass spectrometry was performed on trypsin digests of 19kDa and 16kDa
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proteins (OMP J1 and OMP J2 respectively) to identify amino acid sequences which
were compared to an in silico translation (all 6 reading frames) of the unannotated M.
catarrhalis genome sequence available at GenBank (accession numbers AX067426-
AX067466, comprising 41 contigs ranging in size from 429bp to 261,300bp in length).
Identification of the relevant protein and gene sequence allowed PCR screening and
sequencing primers to be designed.
PCR screening and sequencing of ompJ1 / ompJ2 genes. PCR screening of M.
catarrhalis isolates for ompJ and its genetic variants was performed using standard PCR
techniques and primer pair 19kDres.f and 19kDres.r (primer details for all primers used
are given in Table 1). Expected PCR product sizes were approximately 363bp (ompJ1)
and 333bp (ompJ2) in size. PCR sequencing of the ompJ gene from 14 M. catarrhalis
isolates (representative of the total group of 96 isolates used in this study), was
performed using PCR sequencing primers 19kDseqf, 19kDseqf2, 19kDseqr and
19kDseqr2.
Details of the 14 representative isolates chosen for ompJ sequencing are shown in Table 2.
PFGE genotype / complement phenotypes were obtained by reference to Verduin et al. and
















  Primer                                           Sequence
TABLE 1. List of primers used 
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Preparation of ∆ompJ gene knockout isolates. The regions immediately flanking
the ompJ gene were amplified using primer pair 19kDKO1f.Bam / 19kDKO1r.Pst
(700bp upstream fragment), and primer pair 19kDKO2r.Bam / 19kDKO2f (500bp
downstream fragment).  Both fragments were then digested with Pst I, ligated, and the
1200bp product (minus an internal 410bp fragment of ompJ), re –amplified using
primers 19kDKO1f.Bam and 19kDKO2r.Bam. This PCR product was digested with
BamH I, ligated into plasmid pGEM-7zf(+)  (Promega Corporation), and used to
transform One Shot TOP10 E. coli cells (Invitrogen). Plasmids containing the insert
were selected by PCR analysis of white, ampicillin resistant E. coli colonies. After
extraction, the plasmid was digested using Pst I, and an internal kanamycin resistance
gene cassette (obtained by Pst I digestion of plasmid pUC4K (Amersham Pharmacia
Biotech)) ligated into the ompJ Pst I site. The construct was used to transform One
Shot TOP10 E. coli with selection on Mueller Hinton (MH) agar containing 5µg/ml
kanamycin. M. catarrhalis isolates were subsequently naturally transformed with PCR
amplification products (primer pair 19kDKO1f.Bam / 19kDKO2r.Bam and pGEM-
  Isolate                                   Origin                                        Complement Phenotype
TABLE 2. M. catarrhalis isolates chosen for ompJ gene sequencing.
1.24 - F3.57 = isolates from healthy (colonized) children.  H12 - 97/0233 = positive blood
culture isolates from children. CK16-7 - MT17-3 = isolates from children prone to acute
otitis media
1.24 The Netherlands (1989) RESISTANT
1.39 The Netherlands (1989) SENSITIVE
3.14 The Netherlands (1989) SENSITIVE
3.18 The Netherlands (1989) SENSITIVE
3.9 The Netherlands (1989) RESISTANT
F3.57 The Netherlands (1993) SENSITIVE
H12 The Netherlands (1989) RESISTANT
97/0233 The Netherlands (1997) RESISTANT
25240 ATTC reference isolate RESISTANT
V02 Ghana, Africa     (1995) RESISTANT
CK16-7 New York, USA (1990-92) SENSITIVE
EE11-2 New York, USA (1990-92) RESISTANT
MT17-3 New York, USA (1990-92) SENSITIVE
MT17-6 New York, USA (1990-92) RESISTANT
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7zf(+)ΩompJ∆kanR as template) and selected on Mueller Hinton (MH) agar containing
5µg/ml kanamycin. The presence of the ∆ompJ knockout construct in the chromosome
of kanamycin resistant M. catarrhalis colonies was confirmed by PCR (primers
19kDaKO.ctrlf, 19kDaKO.ctrlr, KanR1 and KanR2), as well as the absence of OMP J
protein expression (established using 1D SDS-PAGE analysis of outer membrane
protein extracts). ∆ompJ2 knockout constructs were prepared in M. catarrhalis isolates 3.9
and 3.18.
Pulmonary clearance study. In order to determine the effect of OMP J on
pulmonary clearance in a mouse model, 2 M. catarrhalis ompJ2 containing gene knockout
mutants (3.9∆ompJ2 and 3.18∆ompJ2) were constructed, and compared to the isogenic
wild-type isolate in a mouse pulmonary clearance study. The mouse pulmonary
clearance protocol was based upon that published by Forsgren et al (15) and Unhanand
et al (39). Basically, M. catarrhalis isolates were grown overnight at 37°C on either MH
agar (wild-type isogenic isolates) or MH agar incorporating 5µg/ml kanamycin (∆ompJ2
mutants), and then grown to mid-log phase in MH broth. A 50µl volume containing 1 x
108 CFU of each isolate was inoculated intra-nasally into the lungs of anaesthetized
BALB/c mice which were sacrificed at ½ hour and 3 hours post-infection{PRIVATE
"TYPE=PICT;ALT=â“"}. Colony counts for surviving M. catarrhalis were performed
on MH agar after overnight incubation at 37oC. Five mice were sacrificed for each
isolate tested (total = 2 x 20 mice). Percentage survival values 3 hours post-inoculation
were calculated by taking the average CFU count of each isolate at time point ½ hour
as 100%. Statistical analysis was performed using a two-tailed unpaired t-test comparing
the difference in lung log10 CFU/ml survivors at times ½ and 3 hours after nasal
inoculation. Further analysis involved generating growth curves for both wild-type and
isogenic ∆ompJ2 mutants in order to verify that no significant difference in growth rates
existed. The animal studies described in this publication were performed in accordance
with the ethical and legal requirements of the Erasmus MC, Rotterdam, and under
approval of the Animal Studies Ethics Committee of the same institution.
Serum bactericidal testing. Serum bactericidal survival for M. catarrhalis
isolates 3.9, 3.18 and their isogenic ∆ompJ2 mutants was based on the protocol
described by Attia et al (1).  Briefly, bacterial cultures were grown to mid-log phase
(approximately 5 x 108 CFU/ml) in Mueller Hinton (MH) broth and diluted 1/1000 in
Veronal-buffered saline containing 0.1% (wt/vol) gelatin. Twenty microliters of this
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bacterial suspension was added to 160µl Veronal buffered saline/gelatin and 20µl of
human pooled serum (or 20µl heat inactivated human pooled serum previously
incubated at 56oC for 30 minutes) added. Ten microliter aliquots of each reaction mix
were plated onto MH agar after 0 and 30 minutes of incubation at 37oC. Four
independent experiments were performed per bacterial isolate, using human pooled
serum (HPS) obtained from 8 healthy adult volunteers. Percentage survival values were
calculated by comparing the means of results at zero minutes and 30 minutes of
exposure to HPS from four independent experiments. Statistical differences between
wild type and ∆ompJ2 isolates were calculated using log10 CFU/ml survival values after
30 minutes of HPS exposure and a two-tailed Student’s unpaired t test (after first
ensuring that there was no significant difference in CFU/ml results after zero minutes
of exposure to HPS).
RESULTS
Identification of OMP J. One-dimensional SDS-PAGE analysis of outer
membrane protein extracts from 48 out of the 96 M. catarrhalis isolates used in this
study, revealed the presence of two putative proteins (of approximately 19kDa and
16kDa) and an association between protein and complement resistant or sensitive
phenotype (Fig. 1). Subsequent tandem mass spectroscopy analysis indicated that the
two proteins consisted mainly of identical polypeptide sequences, indicating that both
proteins were in fact two variants of the same protein. These sequences were found in
only one translated ORF within the whole M. catarrhalis proteome, allowing the protein
and its genomic location to be identified. Using this data, the surrounding ORFs of
ompJ were found to include proteins involved in the recognition and processing of
DNA lesions (uvrC), glycolate metabolism (pgp), glutamyl-tRNA synthetase (gluRS), and
in the suppression of a DnaK-like heat shock protein (data not shown).
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Sequencing and PCR screening of ompJ genes. Sequence analysis of the ompJ
gene from 14 geographically distinct M. catarrhalis isolates indicated that two distinct
phylogenetic lineages existed (GenBank, accession numbers DQ008974-DQ008986
and DQ105644), with 90% identity (over 579bp) between the two most divergent
Fig 1. One-dimensional SDS-PAGE gel of outer membrane
proteins extracted from several complement resistant and
complement sensitive isolates of M. catarrhalis. M = SDS-
PAGE standards. Filled arrows indicate positions of the two
major forms of the OMP J protein. Resistant = complement
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sequences (Fig. 2). This clustering occurred independent of geographical origin of the
isolates. Translation of the 14 gene sequences showed 3 insertion/deletion events
which were common to each cluster, occurring at amino-acids positions 69-71,82-97,
138-144 and 151-153 of the isolate F3.57 sequence. Sequence comparisons of OMP J1
with known protein sequences indicated that the protein was similar to a hypothetical
protein found in the closely related Psychrobacter spp., (GenBank accession number
gi|52853456|ref|ZP_00145674.2|), but contained little sequence similarity with other
known proteins. Secondary structure analysis revealed the putative position of α–helix
and β–sheet regions within the OMP J sequence, providing indications that OMP J may
form a beta-barrel-type structure with considerable structural similarity to a superfamily
of proteins which include the Omp21 protein from Comamonas (Deftia) acidovorans (3, 4),
Neisseria opacity associated protein (Opa) (17), its homologue Neisseria surface protein A
(NspA) (40), and Enterobacter cloacae outer membrane protein X (OmpX) (37, 38). The
position of two of the major insertion/deletion events occurred in a putative external
loop (loop 2) of the predicted barrel-like structure.
PCR screening primers for ompJ were designed using conserved sequences found in
both ompJ1 and ompJ2 genes and yielded positive PCR products in 100% (96/96) of M.
catarrhalis isolates tested (Fig. 3). Of these, 97% (72/74) of complement resistant
isolates generated shorter PCR products of approximately 333bp (ompJ2-like), whilst
74% (14/22) of complement sensitive isolates generated larger PCR products of
approximately 363bp (ompJ1-like). This distribution of ompJ gene to complement
phenotype was found to be highly significant (Fisher’s Exact Test P <0.001).
Importantly, there also appeared to be a significant correlation between the two major
forms of ompJ gene and genetic lineage (as determined by PFGE). In particular, by
cross-referencing the results obtained with 41 isolates previously genotyped by Verduin
et al (42),  it was observed that 22/28 isolates from a short branched lineage harbored
the ompJ2 gene and 9/13 isolates from a longer branched lineage harbored the larger
ompJ1 gene. Further cross-referencing of ompJ PCR data to 55 American isolates
previously genotyped by Hays et al (18), indicated that 50/50 isolates from a short
branched lineage harbored the ompJ2-like gene and 4/5 isolates from a longer branched
lineage harbored the larger ompJ1-like gene (data not shown). These results were highly
significant (Fisher’s Exact Test P = 0.005 and P <0.0001 respectively).
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Fig. 2. (Top) OMP J amino-acid sequences of 14 M. catarrhalis isolates. 25240, 3.14, 3.9, 97/0233,
H12, 1.24, 1.39, F3.57 = Dutch isolates. EE 11.2, CK 16.7, MT 17.3, MT17-6 = American
isolates. V02 = Ghanaian isolate. Dotted line above sequence = signal peptide; filled line above
sequence = β-strands numbered β1 - β8; L1 - L4 = surface exposed loops; T1 - T3 = periplasmic
turns; boxed residues = residues contributing to aromatic girdles; residues in bold type = residues
in β-strands facing the lipids.
(Bottom) Dendrogram of the nucleotide sequences (DICE coefficient with UPGMA). Pheno
= complement phenotype where R = resistant S = sensitive. PFGE = genotypic lineages as
previously determined by Verduin et al, 1994 (1 or 2), and Hays et al, 2003 (a and b).
Fig. 3. Gel showing ompJ PCR screening results obtained for 18 Dutch M. catarrhalis isolates. M =
molecular weight marker (bp). 1 - 18 = Dutch M. catarrhalis isolate F1.11/ F1.3 / 8.3 / 7.13 /
7.10 / 7.2 / 6.12 / 6.2 / 5.12 / 4.22 / 4.16 / 3.24 / 3.21 / 3.18 / 3.14/ 1.38 / 1.12 / 1.9
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PCR screening results did not reveal the presence of  multiple ompJ PCR products
within individual isolates. Further, sequence searching of the only (unannotated) M.
catarrhalis whole genome sequence publicly available (GenBank accession numbers
AX067426-AX067466), revealed the presence of only a single copy of the ompJ gene
(ompJ2) within this isolate.
∆ompJ knockouts and pulmonary clearance studies. Attempts at creating
∆ompJ2 gene knockouts in M. catarrhalis was successful for the complement resistant
isolate 3.9 and complement sensitive isolate 3.18  (Fig. 4), with further studies
indicating that knocking out these ompJ2 gene did not affect the expression of other
outer membrane proteins (Fig. 5).
Diagram and PCR gels showing insertion of kanamycin resistance cassette into ompJ genes of M. catarrhalis
isolates 3.9 and 3.18. Primers: A1 = 19kDaKO.ctrlf, A2 = 19kDaKO.ctrlr; B = 19kDKO1f.Bam; C =
19kDKO2R.Bam;  K1 = KanR1 and K2 = KanR2. 32.9 and 3.18 = isolates 3.9 and 3.18 respectively. ∆ =
the respective isogenic ∆ompJ knockout mutant. Numbers indicate the position of the 5’-end of primers
with respect to the 5’-end of the ompJ gene as obtained from the unannotated M. catarrhalis genome
sequence available at GenBank (accession numbers AX067426-AX067466). The kanamycin resistance
cassette inserted into the ompJ gene is 1240bp in length. Open reading frames in the vicinity of the ompJ
gene include: uvrC  = excinuclease ABC subunit C (gi|46141700|ref|ZP_00147050.2|); pgp = predicted
phosphoglycolate phosphatase (gi|52853459|ref|ZP_00145679.2|), ompJ = hypothetical Psychrobacter
protein Psyc03002166 (gi|52853456|ref|ZP_00145674.2); gluRS = glutamyl- and glutaminyl-tRNA
synthetase (gi|41690542|ref|ZP_00147074.1|);  dnaKs = gene for DnaK suppressor protein
(gi|41690541|ref|ZP_00147073.1|).
uvrC pgp ompJ   gluRS dnaKs
1-1524 + 1429
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Fig. 5. Composite one-dimensional SDS-PAGE gel
showing outer membrane protein profiles of M. catarrhalis
isolates 3.9 and 3.18 along with their respective isogenic
∆ompJ mutants.
The average M. catarrhalis survival in a pulmonary mouse model 3 hours after
inoculation was measured as 23%, 78%, 80% and 92% for isolates 3.9, 3.9∆ompJ2, 3.18
and 3.18∆ompJ2 respectively (Fig. 6). Statistical analysis using a two-tailed unpaired
Student’s t-test indicated a statistically significant decrease in log10 CFU/ml bacterial
survivors after 3 hours for isolate 3.9 (P <0.001), but not for its isogenic ∆ompJ2 mutant
(P = 0.32), isolate 3.18 (P = 0.25) or its isogenic ∆ompJ2 mutant (P = 0.49). Moreover,
both ∆ompJ2 mutants survived in greater numbers than their respective wild-type
parents. Growth curve comparisons showed no difference in exponential growth rate
between the ∆ompJ2 mutants and their respective isogenic isolates, though it was noted
that the final concentration of ∆ompJ2 mutant cells was somewhat lower in the plateau
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Fig. 6. Graph showing percentage pulmonary survival in a mouse challenge study for two wild-type isolates
of M. catarrhalis and two isogenic ∆ompJ2 gene knockout mutants. 3.9 and 3.18 = wild-type isolates 3.9
(complement resistant) and 3.18 (complement sensitive) respectively. ∆ompJ2 = respective isogenic ompJ2
gene knockout mutant. Percentage survival was determined by comparing CFU/ml values 3 hours post-
inoculation with CFU/ml values ½ hour post-inoculation. Data are representative of 5 independent
experiments. Error bars indicate SEM using percentage data.
Serum bactericidal testing.  Serum bactericidal survival results for M. catarrhalis
isolates 3.9, 3.18 and their respective isogenic ∆ompJ2 mutants are shown in Figure 8.
No significant difference was observed between wild-type isolate 3.9 and its ∆ompJ2
mutant in either HPS or heat-inactivated HPS (P = 0.44 and 0.16 respectively), though
percentage survival values were reduced for the 3.9 ∆ompJ2 knockout isolate in both
HPS and inactivated HPS. The complement sensitive isolate 3.18 actually showed an
increase in survival in both HPS and heat-inactivated HPS. However, the significance
of any conclusions that could be drawn were limited by the detection limit of the
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Fig. 7. Growth curves for two Moraxella catarrhalis wild-type isolates (3.9 and 3.18) and
isogenic ∆ompJ2 gene mutants (3.9∆ompJ2  and 3.18∆ompJ2).
Fig. 8. Effect of 10% (vol/vol) human pooled serum (HPS) and 10% heat-inactivated HPS
on the percentage survival of M. catarrhalis isolates 3.9 (complement resistant)  and 3.18
(complement sensitive) compared to their respective ∆ompJ2 gene mutants. Colony counts
were performed at time zero and 30 minutes after addition of serum, with percentage survival
being calculated relative to time zero. Standard error bars are calculated from the means of  4
independent experiments.
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DISCUSSION
Early studies on the outer membrane proteins of M. catarrhalis identified and
characterized eight major proteins within this species, ranging from 98kDa to 21kDa
and named OMP A to OMP H respectively (29). Several of these OMPs have now
been characterized and include proteins involved in iron acquisition e.g. CopB (7),
LbpB/A (6) and TbpB (36), fatty acid uptake (5), and adhesion (22, 23, 26). A role for
some of these proteins in M. catarrhalis virulence and pathogenicity has been suggested,
including the UspA2 (1, 41) and OMP E (30) proteins, which appear to facilitate serum
resistance. Other experiments have shown that a CopB binding monoclonal antibody
(Mab10F3) could enhance the clearance of M. catarrhalis in a mouse pulmonary model,
binding to 70% of M. catarrhalis isolates tested (19). Further, the finding that adults
develop new serum IgG and mucosal IgA to bacterial surface epitopes after
exacerbations of COPD, shows the importance of the humoral immune response to M.
catarrhalis mediated infection (2).
In this publication, 1D SDS-PAGE analysis of outer membrane protein extracts
from several isolates of M. catarrhalis, revealed the presence of a small and novel major
outer membrane protein (OMP J), which was found to exist in two major forms, with
molecular weights of approximately 19kDa and 16kDa (OMP J1 and OMP J2
respectively). Sequence analysis and database searching indicated a limited homology
between the OMP J protein and ompJ gene with other known protein and gene
sequences, with the possible exception being a hypothetical protein found in the closely
related Psychrobacter sp. However, secondary structure prediction for OMP J indicated
that the protein might possess a barrel-like tertiary structure, which taken in context
with the presence of a signal sequence, suggests that OMP J may be an integral
membrane protein. Indeed, the sequence/structure results suggest that OMP J belongs
to a superfamily of proteins that include the OPA (opacity) family of proteins of
Neisseria species, a family of proteins which mediate bacterial adherence to epithelial cells
by interacting with (for example) the receptors for the human carcinoembryonic
antigen cell adhesion molecule (CEACAM) on human polymorphonuclear phagocytes.
Other members of this superfamily include the Neisseria surface protein A (NspA), a
highly conserved protein of unknown function, but which is a promising vaccine
candidate against both Neisseria meningitidis and Neisseria gonorrhoeae (27, 40). Structurally,
the major difference between the two forms of OMP J seems to reside in the deletion
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of 12 amino acids forming part of a putative loop 2 region, though the consequences of
this deletion with respect to the function and antigenic properties of the two proteins
has yet to be determined.
PCR screening of isolates suggested that only a single copy of the ompJ gene is
present in the M. catarrhalis species and that it may be found in 100% of isolates,
indicating a significant role for OMP J in the M. catarrhalis life-cycle. No clear indication
of the likely function of OMP J was obtained by inspecting neighboring ORFs, which
appeared to comprise a mix of putative housekeeping genes involved in various
metabolic and DNA repair activities. Of note however, the direction of transcription of
the ompJ gene lies in the opposite orientation to neighboring ORFs.
A statistically significant association between the two major forms of OMP J,
genetic lineage, and complement phenotype, was observed in diverse geographical
isolates. However, serum resistance experiments using two ∆ompJ2 mutants did not
indicate a significant role for OMP J2 in facilitating complement resistance. It seems
likely that the association between OMP J1 and OMP J2 with complement phenotype
is simply a consequence of their association with different genetic lineages, lineages
previously associated with the differential expression of virulence traits (8). In fact,
most evidence implicates the UspA2 outer membrane protein as the major contributor
to the complement resistance phenotype within this species (1,41).
Previous investigations have shown that alteration in the expression of outer
membrane proteins and LOS in M. catarrhalis may significantly impact on the in-vivo
clearance of isogenic mutants in a mouse pulmonary model of infection (25). Studies
investigating the role of ompJ2 in the clearance of M. catarrhalis from the lungs of mice
showed that the absence of OMP J2 resulted in a reduction in bacterial clearance from
the lungs, suggesting that OMP J2 may actually be a target for the immune system.
 In this publication, the authors identified and characterized a novel outer
membrane protein (OMP J) of M. catarrhalis which appears to be present in two major,
lineage specific, forms. Further, the ompJ gene appears to be universally present within
the species and may play a role in immune-mediated bacterial clearance from the lungs.
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ABSTRACT
A novel major outer membrane protein that exists in 2 major forms, named
OMP J1 and OMP J2, has recently been described in Moraxella catarrhalis, a bacterium
associated with nosocomial infections and respiratory tract disease in both children and
adults. In order to investigate the role of OMP J1 and OMP J2 in the immune response
against this bacterial pathogen, the respective proteins were cloned and used in an
ELISA protocol to investigate the total serum IgG response in groups of children
suffering from acute otitis media, as well as children/young adults with no acute otitis
media disease. Additionally, passive immunization studies were performed in a mouse
pulmonary model of infection using anti-OMP J1 and anti-OMP J2 rabbit
hyperimmune sera. ELISA results indicated that the total serum IgG response remained
constant during the first two years of life, and that no significant difference in total
serum IgG could be found between acute and convalescent sera within groups of
children suffering from acute otitis media. However, a significant difference was
observed in anti-OMP J1 and anti-OMP J2 total IgG reactivity between children and
young adults. Passive immunization using hyperimmune serum raised against OMP J1
resulted in an almost significant reduction in the percentage bacterial survival of an
OMP J1 expressing M. catarrhalis isolate in the lungs of mice (P = 0.06). These results
suggest that OMP J1 and OMP J2 are immunogenic in humans and that antibodies
against these proteins help facilitate bacterial clearance from the lungs of mice.
INTRODUCTION
Over the last few decades, the nature of the bacterium Moraxella catarrhalis has been
redefined from a commensal to an organism with pathogenic potential in its own right
(5, 29). It is currently known that the bacterium may be associated with a variety of
respiratory tract infections in both adults and children, including exacerbations of
COPD (25) and acute otitis media (27). Further, nasopharyngeal colonization is very
common in early childhood and high rates of colonization are associated with an
increased risk of otitis media disease (7).
Several studies have indicated the role of the immune response, and in particular the
antibody response, to M. catarrhalis infection (6, 9, 18), with a highly significant
correlation having been observed between the level of specific anti-M. catarrhalis IgG3
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and certain heavy chain IgG (Gm) phenotypes in patients with chronic/recurrent
sinusitis (12). Further, the development of new serum IgG raised during M. catarrhalis
mediated exacerbations of COPD has been reported (1).
Several research groups are currently in the process of identifying and
developing an effective vaccine against M. catarrhalis (20), with particular emphasis
having been placed on a range of outer membrane proteins (OMPs), as well as  the
lipooligosaccharide/lipopolysaccharide (LOS/LPS) as potential candidates. The M.
catarrhalis OMPs identified as putative vaccine candidates comprise proteins associated
with bacterial pathogenicity and ion/nutrient acquisition. These include the
immunoglobulin D-binding protein (MID) (10), the major heat-modifiable protein
OMP CD (30), lactoferrin/transferrin receptors  (3, 31), the hemin utilization protein
(HumA) (11), OMP E (involved in fatty acid transport) (22) and the ubiquitous surface
proteins A1 and A2 (UspA1 and UspA2), (2),  though the usefulness of UspA2 has
recently been questioned (21). M. catarrhalis LOS linked to immunogenic outer
membrane proteins has been shown to be a promising multi-component vaccine
combination (13, 15, 16).
Recently, a novel major outer membrane protein of M. catarrhalis that exists in
a 19kDa (OMP J1) and a 16kDa (OMP J2) form, has been described, with each form
being significantly associated with particular M. catarrhalis genetic lineages (14). In order
to assess the immune response to OMP J and its possible potential as a putative vaccine
candidate, the immune response to two recombinant OMP J1 and OMP J2 proteins
was investigated. To this end, the ompJ genes from M. catarrhalis isolates V31 (ompJ1)
and 3.9 (ompJ2) were cloned and expressed in Escherichia coli BL21 (DE3) cells and used
in an ELISA to determine the total serum IgG response to OMP J1 and OMP J2
proteins in (Finnish) children presenting with acute otitis media (AOM), and in (Dutch)
children/young adults presenting with non-AOM related respiratory disease (i.e.
allergies). The AOM sera were used as a model for human M. catarrhalis infection, with
the sera from patients suffering respiratory allergies serving as a control group.
Recombinant OMP J1 and OMP J2  proteins were also used to generate hyperimmune
sera in rabbits for use in mouse passive immunization experiments assessing the role of
anti-OMP J antibodies in mediating M. catarrhalis clearance.
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MATERIALS AND METHODS
Expression of OMP J proteins and polyclonal antibody production. Cloning and
expression of OMP J1 and OMP J2 was achieved by PCR cloning the ompJ1 gene from
M. catarrhalis isolate V31 and the ompJ2 gene from M. catarrhalis isolate 3.9 into the
cloning and expression vector pET-11c (New England Biolabs Inc) using His-tagged
primer 19kD.XP.Nhe (5’-ACGTGCTAGCCATCACCATCACCATCACGCCATCAG
CTATGGCAATTCT-3’) and primer 19kD.XP.Bam (5’-ATCGGGATCCTTAGAAA
GCCAAATGAGCGCC-3’), followed by transformation into BL21(DE3) E. coli cells.
After sequencing of the cloned inserts to ensure that they contained the correct gene
sequence, protein expression was facilitated by induction of phage T7 RNA polymerase
via the addition of IPTG to log phase cells grown in LB medium. After sonification,
the relevant protein was purified by nickel-column absorption / elution, followed by
dialysis to remove the imidazole. Finally, the protein was re-solubilized in 8M urea
ready for immunization into rabbits (performed by Eurogentec S.A., Belgium). To
renature the OMP J proteins, a variation of the method described by Oomen et al (23)
and Vandeputte-Rutten  et al (28) was used. Basically, the denatured protein was diluted
5 times in 20mM ethanolamine (pH 10-11) containing 1% (wt/vol) detergent SB14,
ensuring that the pH of the ethanolamine solution was 1.5 –2 times above the
calculated isoelectric point of the OMP J proteins. The protein solution (approximately
1mg/1ml) was then incubated overnight at room temperature, with 100µg aliquots
being used to immunize rabbits. Final bleeding occurred 3 months after initial
vaccination. The reactivity of OMP J1 and OMP J2 hyperimmune sera was tested by
Western blotting a 1 in 30,000 dilution of serum against the outer membrane protein
extracts of M. catarrhalis isolates CK16-7 and V31 (which express OMP J1), and isolates
V02, 97/951 and 97/0233 (which express OMP J2 ).
OMP J ELISA.  An in house OMP J ELISA protocol was developed using cloned,
and renatured OMP J1 and OMP J2 proteins coated onto the surface of 96-well
microtitre plates at a concentration of approximately 0.15µg/well. Plates were blocked
using a solution containing PBS/0.05% Tween 20 (vol/vol) and 1% BSA (wt/vol) with
sera to be tested being diluted 1/250 in PBS prior to use. Secondary total anti-human
IgG antibody (Sigma A1543) was used at a 1/20000 dilution with 30 minutes allowed
for color development. All sera were tested in duplicate and 4 negative PBS controls
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were included per ELISA plate. Optical density (OD) readings were measured at a
wavelength of 405nm.
Three different serum panels were tested using the OMP J1/OMP J2 ELISA,
comprising: 1) a panel of 117 acute and convalescent sera obtained from Finnish
children presenting with an episode of acute otitis media (AOM) with effusion (part of
the Finnish Otits Media (FinOM) Cohort study (24)), with an age range of 2 – 24 months
(mean = 11 months); 2) a panel of 16 sera obtained from Dutch children with no otitis
media disease but presenting at the Erasmus MC with a variety of respiratory ailments
for which clinical chemistry analysis of serum had been requested (age range 8 –29
months, mean = 16 months); and 3) a similar panel of 68 sera obtained from Dutch
children/young adults with no otitis media disease but presenting at the Erasmus MC
with a variety of respiratory ailments (age range 3 – 18 years , mean = 7.9 years).
Convalescent sera obtained from the Finnish children were taken 2-4 weeks (14 – 42
days) after initial diagnosis of AOM (acute phase serum), with middle ear fluid for
bacterial culture being collected after myringotomy. Further, based on the AOM
effusion culture results, the Finnish AOM sera could be subdivided into 3 subgroups
comprising 22 children presenting with an M. catarrhalis culture positive AOM effusion,
46 children with a bacterial positive (other than M. catarrhalis) AOM effusion, and 49
children presenting with AOM effusions from which no bacteria were cultured.
Passive immunization studies. Passive immunization experiments studied the
effect of hyperimmune rabbit serum raised against OMP J1 and OMP J2 proteins on
the ability of BALB/c mice to clear homologous M. catarrhalis isolates in a mouse
pulmonary clearance model. In total, 40 BALB/c mice were used for passive
immunization experiments, utilizing 5 mice per experimental group. Pre- and post-
immunization groups were immunized with 200µl of pre-immunized and 200µl of
post-immune rabbit serum respectively at 24 hours and 1 hour prior to intranasal
inoculation of 50µl bacterial culture containing 1 x 108 CFU M. catarrhalis. Mice were
sacrificed 3 hours after intra-nasal inoculation and CFU counts on lung homogenates
performed. Percentage survival was calculated by comparing the percentage CFU
survival of M. catarrhalis in the pre- and post-immunization groups compared to the
average survival (normalized to 100%) of a group of 5 mice immunized with 200µl PBS
and sacrificed at the initiation of the experiment (t = 1/2 hour post-nasal inoculation).
This method was based on that previously published by Forsgren et al (10). All of the
animal studies described in this publication were performed in accordance with the
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ethical and legal requirements of the Erasmus MC, Rotterdam, and under approval of
the Animal Studies Ethics Committee of the same institution.
RESULTS
Expression of OMP J proteins and polyclonal antibody production. The
cloning and expression of recombinant OMP J1 (M. catarrhalis isolate V31) and OMP J2
proteins (M. catarrhalis isolate 3.9) using the pET11 plasmid system and E. coli
BL21(DE3) cells, yielded protein products of approximately 19kDa and 16kDa
molecular weight respectively. The identity of the putative OMP J protein products was
verified using MALDI-TOF and PCR sequencing of plasmids pET11cΩompJ1 (V31)
and pET11cΩompJ2 (3.9). Hyperimmune serum raised against recombinant OMP J1
and OMP J2 proteins in rabbits were shown to specifically react against OMP J protein
present in M. catarrhalis outer membrane extracts by Western blotting (Fig 1).
OMP J1 and OMP J2 ELISA.  Results using an in house developed ELISA
indicated that both anti-OMP J1 and anti-OMP J2 antibodies were present in all of the
serum panels tested. With respect to age, the total IgG response to both OMP J1 and
OMP J2 proteins remained constant for all children suffering AOM episodes between 2
and 24 months, and showed a steady increase with age for the non-AOM 3–18 year
group (Fig. 2a). This increase in OMP J1 and OMP J2 IgG reactivity with age meant
that a statistically significant difference was observed in ELISA results between AOM
and non-AOM sera for the 3–18 year group (Fig. 2b).
Analysis of sera obtained from children suffering AOM episodes as a single
group indicated no significant difference in anti-OMP J1 or anti-OMP J2 total IgG
between acute and convalescent sera (P = 0.27 and P = 0.50, respectively). However,
convalescent sera were found to exhibit an increased ELISA reactivity against OMP J1,
but a decreased reactivity against OMP J2. This outcome was consistent (but not
statistically significant) when AOM sera were sub-divided into 3 groups according to
the organism isolated from their respective middle ear effusions (Fig. 2c). Further
comparison of these 3 AOM sub-groups with each other yielded no significant
differences in OMP J1 and OMP J2 ELISA reactivity (data not shown).
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FIG. 1. Western blot showing reactivity of rabbit OMP J1 and OMP J2  hyperimmune sera against outer
membrane protein  extracts from a selection of M. catarrhalis isolates. M = Molecular weight marker with
cloned OMP J1 protein. 1, 2 = M. catarrhalis isolates CK16-7 and V31 (OMP J1). 3, 4, 5 =  M. catarrhalis










M     1     2     3      4     5       1     2      3     4     5
Cloned
OMP J1
Chapter 8                                                                                                    The immune response to OMP J
130
FIG. 2. a) ELISA results showing
total serum IgG reactivity to M.
catarrhalis OMP J1 and OMP J2
proteins in different population
groups and ages. a Sera obtained
from 69 Dutch children/young
adults (3 - 18 years) with no AOM
disease. b Sera obtained from 117
Finnish children (2 - 24 months)
during and after an acute otitis
media with effusion episode.
b) Statistical differences in total
serum IgG response to M.
catarrhalis OMP J1 and OMP J2
proteins in the convalescent phase
serum of children with AOM
compared to 2 age groups (single
serum only) with no AOM disease.
a AOM group age range 2 - 24
months. b Non-AOM group age
range 8 - 29 months. c Non-AOM
group age range 3 - 18 years. P =
statistical significance of mean
total serum IgG  reactivity
calculated using the unpaired
Student’s t test.
c) Total IgG immune response of
children suffering from an acute
otitis media episode with effusion.
OMP J1 and OMP J2 = M.
catarrhalis OMP J1 (isolate V31)
and OMP J2 (isolate 3.9) proteins
cloned and expressed in E. coli
BL21(DE3) cells. a = serum taken
during an acute AOM episode
presenting with effusion; c =
convalescent serum taken
approximately 4 weeks (range 14-
42 days) after acute AOM episode.
M. catarrhalis = M. catarrhalis grown
from middle ear effusion; Bacterial
AOM = bacterial species other
than M. catarrhalis grown from
middle ear effusion; Other AOM
= No bacteria grown from middle
ear effusion;  No AOM = control
children not presenting with AOM
symptoms. P values were
calculated using the Student’s
paired t-test. Sera were diluted
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Passive immunization studies. Passive immunization studies using rabbit 
hyperimmune serum raised against OMP J1 and OMP J2 proteins showed a trend 
towards a reduction in M. catarrhalis survival in the lungs of mice immunized with the 
corresponding OMP J hyperimmune serum (Fig. 3). Indeed, this reduction in survival 
was found to be almost statistically significant in mice passively immunized with OMP 
J1 hyperimmune serum and challenged with the OMP J1 expressing M. catarrhalis isolate 
V31 (2-tailed unpaired Student’s t test, P = 0.06). However, no significant difference in 
percentage M. catarrhalis survival was observed in mice passively immunized with OMP 
J1 hyperimmune serum and challenged with OMP J2 expressing M. catarrhalis isolate 
3.9, or in mice passively immunized with OMP J2 hyperimmune serum.  
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FIG. 3. Effect of passive immunization using hyper-immune rabbit serum raised against cloned OMP J1 
and OMP J2 proteins (obtained from M. catarrhalis isolates V31 and 3.9 respectively) on the percent 
survival of  M. catarrhalis V31 and 3.9 in the lungs of BALB/c mice. Mice were immunized with 200l of 
the respective pre-immune (Pre) or hyperimmune (OMP J1 or OMP J2) serum at time periods 24 hours 
and 1 hour (booster) prior to nasal inoculation of 1 x 108 CFU bacteria. Mice were sacrificed 3 hours after 
nasal inoculation. Surviving bacteria % = percentage surviving M. catarrhalis bacteria compared to the 
number of bacteria detected at initiation of the experiment. Five mice were used per study group. Error 
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DISCUSSION
Serological studies using recombinant OMP J proteins showed that
hyperimmune sera raised against recombinant OMP J1 and OMP J2 proteins
recognized both OMP J1 and OMP J2, indicating that the deletion of a small 12 amino-
acid segment in loop 2 of OMP J2 did not seriously affect total IgG production against
the OMP J2 protein. However, the presence of this additional 12 amino-acid segment
in OMP J1 would be expected to provide extra epitopes against which OMP J1-specific
(and possibly neutralizing) antibodies could be targeted. Further, the deletion of the
loop 2 segment could in theory result in an alternative OMP J2 conformation, possibly
leading to the shielding or exposing of important neutralizing epitopes.
When related to age, the reactivity of serum IgG against both OMP J1 and
OMP J2 proteins remained constant during the first 2 years of life for both AOM and
non-AOM groups, but steadily increased from 4–18 years of age (in the non-AOM
group tested). Further, a significant difference between mean total IgG reactivity
between the AOM and 3-18 year non-AOM group, but not the AOM and 8-39 month
non-AOM group, was observed. This observation could be a consequence of an
increased exposure to M. catarrhalis over time, resulting in an increase in isolate-specific
anti-OMP J IgG titers, possibly contributing to a decrease in M. catarrhalis colonization
with age.
The fact that no significant difference was observed in total serum IgG
reactivity between acute and convalescent sera in children with AOM, indicates that
anti-OMP J1 and anti-OMP J2 IgG antibodies are not important in the etiology of
AOM disease, even though OMP J1 and OMP J2 are indeed immunogenic. Further,
Mathers et al (19) reported that during AOM episodes, a rise in specific anti-M.
catarrhalis OMP IgG was detectable in 83% of children 8 months of age or older, and
also in 17% of younger children. Therefore, if OMP J were important in M. catarrhalis
mediated AOM infections, then a rise in anti-OMP J IgG would have been expected to
occur. However, there are indications to suggest that the antibody response to M.
catarrhalis otitis media infection in children may (occasionally) be limited to the middle
ear, with systemic antibody failing to be developed in a uniform manner (8). Also, our
AOM groups may not have been large enough to detect changes in acute and
convalescent sera. Interestingly, a consistent increase in anti-OMP J1 total IgG
antibody was observed between acute and convalescent sera, whilst the same sera
showed a consistent decrease in anti-OMP J2 total IgG antibody. In this context, recent
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research has suggested that bacterial colonization of the nasopharynx does not
necessarily lead to an increase in specific mucosal IgA antibodies, with for example M.
catarrhalis anti-OMP E antibody actually showing a decline in response to colonization
(4). Finally, the OMP J1 and OMP J2 total serum IgG response appeared to be similar
in all AOM subgroups, including those subgroups where no evidence for M. catarrhalis
mediated AOM was found. These results could indicate that OMP J cross-reactive
antibodies might be found in human serum. Indeed, mouse anti-Neisseria meningitidis and
anti-Neisseria lactamica sera have been shown to recognize M. catarrhalis 77, 62 and 32
kDa outer membrane antigens (26), indicating a possible interaction between human
anti-Neisseria hyperimmune sera and M. catarrhalis proteins.
Serum levels of specific IgG and IgA have previously been shown to be
correlated with pulmonary clearance of M. catarrhalis in a mouse model of infection
(17). Therefore, we used a similar model to investigate the effect of passive
immunization using OMP J1 and OMP J2 hyperimmune sera on the pulmonary
clearance of M. catarrhalis in mice. These studies yielded interesting results, in that an
almost significant decrease in M. catarrhalis survival was observed in mice passively
immunized with OMP J1 hyperimmune serum and challenged with an OMP J1
expressing isolate, but not in mice passively immunized with OMP J2 hyperimmune
serum and challenged with an OMP J2 expressing isolate. These results suggest that the
“intact” loop 2 region of OMP J1 may play a role in the immune response against M.
catarrhalis infection, with the truncated loop 2 of OMP J2 expressing isolates providing
some protection against killing for OMP J2 expressing isolates. This finding could
impact on any future plans to utilize the OMP J proteins as potential vaccine
candidates, not least because previous research has indicated that the OMP J2 gene is
significantly associated with M. catarrhalis lineages exhibiting an increased virulence
potential (14).
In this article, investigations were performed into the immune response against
the recently described M. catarrhalis outer membrane proteins OMP J1 and OMP J2.
The ultimate goal of the research was to indicate whether OMP J could be useful as a
potential vaccine candidate against M. catarrhalis, with the results suggesting a complex
interaction between the host and these 2 forms of OMP J protein. In particular, the
protein appears not to play a major role in AOM mediated disease, but alternatively
may play a role in bacterial clearance from the lungs. Further research is necessary to
clarify the exact role of the OMP J protein in the immune response against M.
catarrhalis.
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Abstract
A hemolytic bystander assay was used to assess the functional serum mannose-
binding lectin (MBL) activating capacity of 5 isolates of Moraxella catarrhalis obtained
from children who suffered recurrent acute otitis media episodes. Results showed that
this organism is only a poor activator of the lectin pathway of complement activation,
with subsequent consequences for the etiology of otitis media by this organism.
1.  Introduction
Moraxella catarrhalis is a commensal bacterium associated with both the
colonization and infection of adults and children. In particular, the bacterium is most
often associated with respiratory tract infections, including acute and chronic otitis
media and acute exacerbations of chronic obstructive pulmonary disease (COPD) [1].
In terms of the immunological response to M. catarrhalis, research has indicated that
colonization/infection leads to the generation of opsonic antibodies against the relevant
isolate [2], and that complement resistant isolates (which possess an increased virulence
potential) possess the ability to  bind vitronectin [3] and/or complement component
C4b-binding protein [4]. However, there have as yet been no publications into the
possible role of the mannose-binding lectin (MBL) arm of the complement system in
the immune response to M. catarrhalis.
Mannose-binding lectin (MBL) is a high-molecular-weight protein, which is
present in blood plasma at low concentrations (1.7 µg/ml), and which forms the initial
component of the lectin pathway of the complement system. The protein acts by
binding to specific sugar residues (i.e. mannose, N-acetylglucosamine, and fucose)
present on the surface of microorganisms, leading to the subsequent activation of the
(“innate”) MBL arm of the complement cascade system. In man, MBL deficiencies are
quite common, with MBL gene polymorphisms leading to differential MBL expression
levels, which in turn have been associated with susceptibility to several different types
of infection [5]. In this brief report, a functional MBL assay was used to characterize M.
catarrhalis as a weak or potent activator of the MBL arm of the complement system.
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2.  Materials and Methods
2.1 Bacterial isolates
Five isolates of M. catarrhalis were tested for MBL activating capacity, all obtained
from children who suffered recurrent acute otitis media episodes. Three isolates
(isolates 2040-1, 3001-14/20 and 4017-7) had been previously determined to be
complement resistant and 2 isolates complement sensitive (isolates 3053-14 and 3007-7)
via a simple “spot and drop” test [6,7].
2.2 Functional MBL assay
The functional MBL assay used to measure M. catarrhalis-induced MBL activation in
this article was based upon that previously published by Kuipers et al [8], which makes
use of microorganism-induced MBL activation in a dilution series of pooled human
serum, followed by subsequent C5b6-mediated bystander hemolysis of chicken
erythrocytes in the presence of a standardized concentration of MBL-deficient human
serum. In this assay, the degree of MBL activation of microorganisms is related to the
MBL-activating capacity of a standard isolate of the yeast Saccharomyces cerevisiae (in order
to eliminate inter-experimental variation), using pooled human serum containing a
known MBL concentration. With regard to M. catarrhalis testing, twelve different
dilutions of the 5 M. catarrhalis isolates to be tested (previously grown on Columbia
blood agar and resuspended to an OD660 of 1.0, equivalent to approximately 1.5 x 108
CFU/ml), or 3 x 105 S. cerevisiae cells, were prepared in veronal buffered saline
containing Ca2+ and Mg2+ (VSB++). A checkerboard titration was then performed
against dilutions of the standard pool of human serum. After incubation, the degree of
bystander erythrocyte lysis was translated into the number of active sites per
erythrocyte (Z value) using the equation of Borsos and Rapp [9]. As a control, pre-
incubation of the standard human pooled serum with 2.5 mg/well mannose (which
binds and blocks MBL binding), followed by repetition of the MBL activation
experiments, was performed in order to indicate whether the bystander hemolysis
attributable to M. catarrhalis was a consequence of MBL-specific activation. Activation
of the alternative pathway of the complement system was excluded by testing in
ethylene-glycol bis-amino-tetraacetic acid – veronal buffered saline [10]. The relative
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MBL activation of M. catarrhalis was read off at a Z value of 0.2 (calculated as: Z M.
catarrhalis / Z S. cerevisiae) and M. catarrhalis-mediated MBL activation ranked alongside other
pathogenic bacteria using previously published data [8]. S. cerevisiae was used as the
standard reference as this was the first reported microorganism to be associated with
MBL [11], and the yeast cell wall of this organism is rich in mannan.
3.  Results and discussion
The MBL activating capacity (as a measure of the level of bystander hemolysis
of chicken erythrocytes) for the 5 M. catarrhalis isolates tested is presented in Fig. 1.,
with no difference being observed in MBL activating capacity between the complement
resistant and complement sensitive isolates. A comparison of the M. catarrhalis results
with bacterial species previously determined to be weak/potent activators of MBL is
shown in Table 1. Experiments using mannose as a competitor for MBL activation
showed that pre-incubation with mannose had a negative effect on the ability of M.
catarrhalis to activate MBL (Fig. 1), indicating that M. catarrhalis MBL activating activity
in the functional assay (though weak) was indeed a specific phenomenon.
These results indicate that M. catarrhalis is only a weak activator of the MBL
arm of the complement system. In theory, this lack of MBL activation could be
advantageous to the organism in allowing it to remain “hidden” from the MBL arm of
the complement system (i.e. protected from lectin pathway-induced complement
activation). In this scenario, serum MBL levels would be unlikely to influence M.
catarrhalis colonization/infection. However, it should be noted that heavily
mannosylated immunoglobulin A (IgA) is also found at tissue surfaces [12], and an
interaction between IgA binding and MBL activation in M. catarrhalis mediated infection
cannot be discounted at present.
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Fig. 1. Composite graph showing average
MBL activation by M. catarrhalis (with and
without the addition of competing
mannose) and the yeast Saccharomyces
cerevisiae (used as a standard MBL
activating control organism to which
organisms are compared in order to
eliminate inter-experiment variation). Z
value = mean number of active sites per
chicken erythrocyte determined by the
functional bystander assay. Experiments
were performed in triplicate. Note the
reduction in MBL activating capacity (Z
value) of M. catarrhalis after pre-incubation
of standard MBL containing human
pooled serum with mannose (indicating
the specificity of M. catarrhalis MBL
activation). The 5 M. catarrhalis isolates
used were all Dutch isolates, identification
numbers 2040-1, 3001-14/20, 4017-7,
3053-14 and 3007-7.
Table 1.  Comparison of potent and weak MBL activating microbial species (relative to the standard
organism S. cerevisiae) as determined using a functional bystander hemolysis assay.
a Z microbe (OD 1.0) / Z S.cerevisiae (control) = ratio
used to rank microorganism MBL
activating capacity with respect to the
standard reference organism S. cerevisiae,
where Z = -ln (1 - fraction erythrocytes
lysed) a measure of the mean number of
MBL active sites per chicken erythrocyte
calculated using the equation of Borsos
and Rapp (1963). *b = The MBL
activating capacity of these organisms
exceed the maximum limit of this test at
an OD660 of 1.0.
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ABSTRACT
A preliminary screening study of 6 Moraxella catarrhalis isolates from primary
school children in the Netherlands identified a small 3.5kb plasmid (pEMCJH03),
containing four open reading frames, which encoded three mobilizing and one replicase
proteins. Insertion of a kanamycin containing transposon (yielding pEMCJH04)
allowed selection and isolation of the plasmid in E. coli. Natural transformation of
pEMCJH04 was successful in 25% (3/12) of non-isogenic isolates, with no link
between (lack of) transformability and genetic lineage or (lack of) transformability and
complement phenotype, though the transformation efficiency was found to be rather
low at approximately 615 CFU/µg (range = 60 – 1040 CFU/µg ). This is only the
second publication detailing a plasmid isolated from this important respiratory
pathogen, and the ability to clone and express foreign proteins in M. catarrhalis using
pEMCJH04 could help in the development of a vaccine expression vector, as well as
providing a useful tool for studying promoter activity and in complementation studies
of gene knockout mutants.
Moraxella catarrhalis is a common commensal of the human upper respiratory
tract which has been associated with a number of disease states including acute otitis
media in children (Catlin, 1990; Faden et al., 1994a; Faden et al., 1994b) and both acute
and chronic bronchitis in adults (Hager et al., 1987; Nicotra et al., 1986). Nosocomial
spread and outbreaks of this pathogen have been reported (Cook et al., 1989; Patterson
et al., 1988) as well as cases of near fatal pneumonia (Dyson et al., 1990). Moreover,
there exists a very high prevalence of β–lactamase production within the species
(Thornsberry et al., 2002).  Vaccines against M. catarrhalis are currently being developed
(Chen et al., 1996; McMichael, 2000), though a suitable universal cloning vector for the
expression of M. catarrhalis proteins within this species and other genera has yet to be
fully described and developed. Several studies have investigated the carriage of plasmids
in non-Moraxella catarrhalis species including M. bovis (McDonald and Pugh, 1986), and
environmental Moraxella species (Kawasaki et al., 1992; Rani et al., 1996; Vasudevan and
Paulraj, 1994), though only one plasmid has been fully characterized and sequenced
within the M. catarrhalis species (plasmid pLQ510). This 12kb plasmid pLQ510 (Beaulieu
et al., 1988; Liu and Hansen, 1999) has previously been suggested as a possible cloning
and expression vector, though the size of the plasmid (even without the presence of
inserted genes) could reduce its ability to be efficiently transformed. Here, we report on
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the finding of a small 3.5 kb plasmid in M. catarrhalis, which could possibly fulfill such a
role.
Initial plasmid screening efforts utilized 6 M. catarrhalis isolates (3 colonizing
isolates originally isolated in 1989 from primary school children in Nieuwegein, The
Netherlands, and 3 colonizing isolates originally isolated in 1993 from primary school
children in Heerenveen, The Netherlands). The isolates were retrieved from –80oC
storage and grown overnight (approximately 16 hours) on 5% sheep blood agar at 37oC
until semi-confluent, whereby 1/4 plate of growth was removed and embedded in
agarose blocks according to established pulsed field gel electrophoresis (PFGE)
protocols (Vu-Thien et al., 1999), but without the addition of a restriction enzyme.
PFGE was performed using a CHEF Mapper (BioRad) with a ramping protocol of 6
V/cm constant voltage at 15oC, and a pulse time increased from 2 to 10 seconds for 10
hours. After electrophoresis, the presence of any extrachromosomal plasmid DNA was
detected using ethidium bromide staining. PFGE testing indicated the presence of at
least 3 different extra-chromosomal elements within the range of isolates tested (Fig. 1),
ranging in size from approximately 5kb to 60kb in size. At this point, the smallest
plasmid (pEMCJH03), was isolated from its host (M. catarrhalis isolate 6.12) using the
SV Wizard plus minipreps system (Promega), and recovered by insertion of a
kanamycin encoding transposon using the EZ::TN <KAN-2> insertion kit
(Epicentre). The resultant pEMCJH03 plasmid containing the EZ::TN <KAN-2>
transposon (plasmid pEMCJH04) was rescued in chemically competent E. coli TOP10
cells : F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 deoR araD139∆(ara-
leu)7697 galU galK rpsL (StrR) endA1 nupG (Invitrogen BV), followed by the selection of
kanamycin resistant clones on Mueller Hinton agar containing 5µg/ml kanamycin
(MH5Kan).  A primer walking strategy was then undertaken to sequence both strands
of the plasmid, using the primers provided with the EZ::TN <KAN-2> insertion kit
as the initial pair of sequence primers.
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Fig. 1. Composite picture of extra-
chromosomal elements observed in 4 M.
catarrhalis isolates  recovered from children
living in The Netherlands during the years
1989 and 1993 using native pulsed field gel
electrophoresis. 1 - 4 = M. catarrhalis
isolates 3.21, 5.12N, 6.12K, F6.92 and
F5.82 respectively. Mwt = lambda ladder
molecular weight marker (kbp).
M. catarrhalis isolates to be naturally transformed were grown overnight at 37oC
on Mueller Hinton (MH) agar. The following day, approximately 50ng of plasmid
pEMCJH04 was spotted onto an area of confluent M. catarrhalis growth. The drops
were then allowed to dry and the isolates returned to the 37oC incubator for 2 hours,
after which time the M. catarrhalis cells within the “drop zone” were resuspended in
100ul water and plated onto both MH5kan agar (99µl) and MH agar (1µl positive
growth control). After a further incubation step at 37oC for up to 48 hours, the number
of kanamycin resistant colonies found on the MH5 plates were counted.
Sequencing of plasmid pEMCJH04 revealed that pEMCJH03 (the original
plasmid without transposon insert) comprised 3,510 base pairs with a GC content of
44%, a GC content higher than that of the M. catarrhalis genome (41.7%) as well as the
previously published plasmid pLQ510 (37.9%). Translation of the DNA sequence
followed by database “BLAST” searching (http://www.ncbi.nlM.nih.gov/BLAST/)
showed that the plasmid contained four open reading frames (ORFs), with three ORFs
sharing conserved domain architecture to the mobilization (mob) genes of other
bacterial species, and the fourth ORF comprising a putative replicase gene (replicase
initiator protein). The plasmid contained no pilus synthesis (transfer or tra) genes. A
schematic representation of plasmid pEMCJH03 and pEMCJH04
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Fig. 2. Diagrammatic representation of the 3.5kb mobilizable plasmid pEMCJH03 and the
EZ::TN<Kan2> transposon containing pEMCJH04. mobA, mob B, mobC = genes for putative mobilization
proteins A, B and C respectively. Rep = gene for putative replicase protein. oriV = putative origin of
replication. oriT = putative origin of transfer. * = transposon randomly  inserted into mobC gene. The
nucleotide sequences for pEMCJH03 and pEMCJH04 (pEMCJH03ΩEZ::TN<Kan-2>) are available at
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pEMCJH03 ORF1 encoded a protein comprising   420  amino   acids  whose
N-terminal   half   was  similar  to  the mobilization protein MbeA of Salmonella
enteritidis  (gi|19526579|gb|AAL87013.1|) and the mobilization MobA protein of E.
coli (gi|78698|pir||S04789), exhibiting identities of 27% and 28% over the total
lengths of the translated proteins respectively. At the C-terminal end of the protein was
a highly polar region comprising 8 glutamine, 2 arginine and 2 (non-polar) alanine
amino acids. Functionally, MobA proteins act by binding and nicking double stranded
DNA at the origin of transfer (oriT) site ready for DNA transfer, and are responsible
for re-ligating the cleaved DNA strands once transfer of DNA is achieved. However,
no oriT consensus sequence could be found which would place pEMCJH03 in either
the P-type (YATCCTG/Y), Q-type (TAANWGCG/CCCT) or F-type
(TGCGNNNNGTNT/RNNNC) oriT-relaxase systems (LANKA AND WILLIAMS,
1995). ORF2 encoded a putative MobB protein, with 28% identity to the mobilization
B protein of  plasmid ColA (gi|9507288|ref|NP_040389.1|). It has been
demonstrated that MobB proteins may interact with MobA proteins (in a region
distinct from the nicking-ligating region of MobA), thereby assisting the relaxosome
unit (Perwez and Meyer, 1999).  ORF3 comprised 113 amino acids with homology to
the mobC protein of Pasteurella multocida (gi|10955979|ref|NP_054474.1|) and Proteus
vulgaris (gi|11992063|gb|AAG42421.1| ), with identities of 42% and 38% respectively.
MobC acts together with MobA and MobB proteins to form the relaxosome unit, with
previous research indicating that lack of the MobC protein may lead to a 50-fold
decrease in plasmid conjugal mobilization in some plasmids (Zhang and Meyer, 1997).
The final ORF of pEMCJH03, encoded an E. coli like replication initiator protein
similar to the replication initiator (Rep) proteins of theta-replicating plasmids pColE2
(gi|78570|pir||S04455) and pColE3 (gi|78571|pir||S04456), with protein identities
of 41% and 39% respectively.
A 339bp region of DNA situated immediately downstream of the
putative Rep gene and upstream to the putative mobC gene (Fig. 3), contained 2 sets of
inverted repeats as well as 2 sets of direct repeat sequences. The direct repeat regions
showed some homology to the Rep-binding sequence TGAGACCAGATAA-GCCT-
TATCAGATAAGAGCGCC of the theta-replicating ColE2-type plasmids (del Solar et
al., 1998), as well as homology to a conserved AAGCCTAAATCAGATAACAGCCG
sequence (Expect value 0.085), associated with 2 partially mobilizable plasmids from
the closely related Acinetobacter species (GenBank accession numbers:




and                           gi|6706018|emb|AJ251518.1|ACA251518).
These 2 sets of direct repeats also formed part of 2 larger direct repeat
sequences which may be possible iteron–like sequences. A putative initiator host factor
(IHF) binding sequence  5’ – TACAAGTGATTGTGAAGTTTTTCAAGAA - 3’
(with some similarity to the E. coli IHF consensus sequence 5’ -
T.PyAA…PuTTGa.T.A.PuTT…pYAACtA - 3’ of  Craig and Nash 1984 (often cited
as “YAANNNNTTGATW” where Y = C/T and W = A/T)), was found upstream of
the putative mobA gene and included the extreme 3’-end of the putative mobC gene.
Neither the putative oriV region nor the putative IHF region resembled the
corresponding replication region of the previously published M. catarrhalis plasmid
pLQ510.
Natural transformation of plasmid pEMCJH04 was successful for 25% (3/12)
of non-isogenic M. catarrhalis, though the transformation efficiency was found to be
particularly low at approximately 615 CFU/µg (range = 60 – 1040 CFU/µg ). In our
experience, the agar plate method used for natural transformation is the most
convenient and reliable method for naturally transforming multiple isolates of M.
catarrhalis, though it is possible that other transformation methods, using well
characterized isolates, may yield a greater transformation efficiency. However, M.
catarrhalis has a strong tendency to form aggregates in broth culture, and M. catarrhalis
competence has been associated with the expression of type 4 (MePhe) pili (a putative
virulence trait) in certain isolates (Marrs and Weir, 1990; Luke et al., 2004), a trait not
investigated in our transformation experiments. However, the isolates used for
transformation in this experiment, were chosen to represent: a) the two genetic lineages
present within this species (Bootsma et al., 2000), and b) isolates expressing either
the  complement  resistant  and  complement  sensitive phenotypes  (an   acknowledged
virulence trait of M. catarrhalis) (Verduin et al., 2000). Results however, indicated no
significant difference with regard to transformability with pEMCJH04 and isolates from
the two genetic lineages (2/7 from the clonal lineage transformable, 1/5 from the non-
clonal lineage transformable; Fisher’s exact test p = 1), or transformability and isolates
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exhibiting the complement resistant or sensitive phenotype (2/6 complement resistant
transformable, 1/6 complement sensitive transformable; Fisher’s exact test p = 0.6).
Fig. 3. Putative oriV region of plasmid pEMCJH03. Solid line with arrows = inverted repeat. IR1 =
inverted repeat number 1. Solid line with filled circular ends = putative Rep-binding site similar to ColE2-
type plasmid. Solid line above sequence = direct repeat (putative iteron sequence). Full stops =
diagrammatic representation of the intervening locations of the mob and Rep genes. * = sequence
numbering according to the pEMCJH03 sequence deposited at GenBank (accession number AY167745).
As a final note, the presence of restriction-modification systems (Seib et al.,
2002), and sequence mutations affecting the replication and/or promoter regions of  M.
catarrhalis genes (Bootsma et al., 1996), mean that more research on the transformation
characteristics and stability of this plasmid in M. catarrhalis is necessary if it is indeed to
be used as a cloning/protein expression vector in this species.




GACCTGCGATTTTTACAC GTTTATTTTTG TGGCTTGGTAACTATA GCAAACAGTCAAAACACA C CAAAAATAAAC CCTA
ACTAAGTATATTTTACCTGTGTTTTGACTGTTTGC AACCATTTTTTGGACTTTTTGCAA ATG.. . REPLICASE    ...TGA
CACCAGATAAGCCTAAATCAGATAACAGCCCCAAAAGCGAGCTTTTGGGGTGCCTTTTAGACGGTGCTAGGTTTTTGACAG
 CAGATAAGCCTAAATCAGATAACAGCCGAATCGATAAGCCTTAGTT GGTTAAGGGGG CAGGAAATTCATATTGAACAAAT
GTTTAGTTAAGTGTAGAATAATCATACATCCTTATTAAGGG CAAGCATACTC AAGCCCCACAA AGTGTGCTTG AAATCCT
 TGTAAGGGGAAATCCCCCTTAACC CCCTGCACAATCTTCGTTGCACTGCGATTGTGTTGGGGCAAGCCCCAAACCCCAGTT
AGAAAGACAAAGAAAAAA      ATG … mobC    …. TGA TTGTGAAGTTTTTCAAGAACAAGGGTGCAGGCAGTGC
TACAGCGAGCGTAAATTACTTGTTAGGCAAGGATAGGGATAGGCAAGGGGCTAGGGTGCTACATGGCAATGCAGAGCTTA
CAGCACAGCTTGCAGAGAGCCTAGAGTTTAAACACAAATATACCGTTGGTTGTCTATCATTTGCTGAGCAGGACAAGCTAGA
CGAGAACGCTAAGCGTGAAATC     ATG … mobA  / mobB …
3365*
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The complete DNA sequences for plasmid pEMCJH03 and pEMCJH04
(pEMCJH03ΩEZ::TN<KAN-2>) are available at GenBank, accession numbers
AY167745 and AY453632 respectively.
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The bacterial species known as Moraxella catarrhalis was previously thought to
be a common human commensal bacterium, able to colonize the human respiratory
tract, but exhibiting little pathogenic potential. However, evidence over the last few
decades has brought about a change in our perception of this species, indicating the
clinical relevance of this organism in facilitating disease in both children and adults. In
particular, M. catarrhalis tends to be associated with upper respiratory tract infections in
children (e.g. acute otitis media and sinusitis), but lower respiratory tract infections in
adults (e.g. bronchitis, pneumonia, laryngitis, exacerbations of chronic pulmonary
obstructive disease), with the species occasionally being reported in a selection of non-
respiratory tract associated disease states, including; bacteremia, endocarditis,
conjunctivitis/keratitis, meningitis, ventriculitis, ophthalmia neonatorum, acute
mastoiditis and septic arthritis. There also appears to be a striking difference in the
carriage rates of this organism between children and adults (carriage rates being as high
as 75% in children but only 1 – 3% in adults), as well as a distinct seasonality of
isolation (the winter and spring months showing the greatest rates of isolation). The
possible mechanisms of spread of M. catarrhalis, includes person-to-person transmission
(including intra-familial spread) or spread via environmental contamination, with both
nursery schools and day care centers having been shown as to be important reservoirs
for strain exchange. Further outbreaks of nosocomial infection due to M. catarrhalis
have been regularly documented.
Since M. catarrhalis was acknowledged as a pathogen in human disease, research
has focussed on several key aspects of this species, namely genetic diversity, pathogenic
traits, the immune response and putative vaccine designs. A detailed description of the
current state of knowledge regarding these key aspects of research is given in Chapter
2. This information forms the basis for the research published in this thesis.
Genetic Diversity in Moraxella catarrhalis
Many different methods have been utilized to study the relatedness of different M.
catarrhalis isolates, including protein expression profiling (12), DNA-DNA hybridization
(1, 3, 19), restriction fragment length polymorphism analysis (5, 8), single-adapter
amplified fragment length polymorphism analysis/16S rRNA sequencing (2), randomly
amplified polymorphic DNA analysis (18), and pulsed field gel electrophoresis (11, 17).
However, there is as yet no published and accepted “gold standard” for genotyping this
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species, though unpublished results (Mark Achtman, personal communication) have
indicated that for example multi-locus sequence typing may be useful as the gold-
standard technique for the future.
In Chapter 3, pulsed field gel electrophoresis (PFGE) was used to study a
collection of 129 Moraxella catarrhalis isolates obtained over a 20 month period from 70
children admitted to, or presenting at, the Erasmus MC, Rotterdam, The Netherlands.
Using PFGE, 51 different M. catarrhalis genotypes were identified, with 31% (22/70) of
children being infected with two particularly prevalent M. catarrhalis types, which also
exhibited different protein profiles. Further, 72% (16/22) of the children colonized
with these two predominant types had spent at least one week on two pediatric
intensive care wards within the Erasmus MC. By producing a time-line of colonization
events, it was shown that replacement of one genotype with another could occur within
this environment, though no exacerbation of existing disease or new disease was
observed in any of the children for whom M. catarrhalis genotype changes occurred.
These results indicate that genotype “switching” of M. catarrhalis genotypes occurs in
the nosocomial environment, possibly paralleling events occurring in other closed
environments (e.g. day care centers, at home etc). Moreover, genotype switching did
not lead to the appearance of overt clinical disease, which may indicate that the true
colonization rate of M. catarrhalis in children may be somewhat underestimated.
However, some publications have in fact associated M. catarrhalis with pneumonia and
bronchitis in pediatric intensive care units  (4, 6, 14-16), indicating that M. catarrhalis
may indeed facilitate the onset of overt disease within these environments. Taken
together with our results, it is possible that certain M. catarrhalis genotypes may not
actually be associated with facilitating tangible disease. Alternatively, it is also
conceivable that certain human “genotypes” may be resistant to M. catarrhalis induced
disease.
Chapter 4 also used the PFGE genotyping technique, but this time to investigate
whether vaccination against common serotypes of S. pneumoniae (an organism that
occupies the same biological niche as M. catarrhalis) affects the genetic diversity of M.
catarrhalis isolates colonizing children with a history of acute otitis media episodes. In
total, 41 M. catarrhalis isolates obtained from 13 children vaccinated with pneumococcal
vaccine and 21 M. catarrhalis isolates obtained from 6 children vaccinated with a control
(hepatitis A or B) vaccine were genotyped, indicating the presence of four clusters
comprising a wide variety of genotypes. Moreover, no pattern could be observed
between PFGE cluster and vaccination status, or PFGE cluster and the isolation of
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other (co-colonizing) bacteria. M. catarrhalis PFGE types belonging to different clusters
were found to occur within the same patient over time as well as being associated with
different episodes of acute otitis media in the same patient over time. Further, the vast
majority of isolates 90% (56/62) were found to exhibit the complement resistant
phenotype, though no difference between complement phenotypes was observed
between the vaccinated and unvaccinated groups (Fisher’s Exact Test P = 1). The
results of the investigation indicate that vaccination against S. pneumoniae in older
children does not affect the diverse genetic nature of M. catarrhalis isolates when
compared to a control vaccinated group, implying that a vaccine effective against a wide
range of genotypes of M. catarrhalis will be necessary, even when S. pneumoniae is
removed from the biological niche.
 Chapter 5 utilized high-throughput amplification fragment length polymorphism
(htAFLP) and one–dimensional SDS-PAGE analysis to investigate the
presence/absence of genetic markers within different M. catarrhalis genotypic lineages
and phenotypes (with specific reference to the complement resistance virulence trait).
This study represented the most powerful genotypic analysis of the M. catarrhalis species
yet published, analyzing 2,273 fragment length polymorphisms obtained from a
population comprising 48 different isolates. Moreover, despite the presence of 40
lineage-specific polymorphisms, not one complement phenotype-specific marker was
found. One-dimensional SDS-PAGE analysis revealed the presence of 6 major protein
expression markers significantly associated with complement phenotype. By combining
both lineage-specific and complement-phenotype associated markers, the ability to
specifically identify virulent M. catarrhalis isolates should be enhanced.
Chapter 6 used PFGE to investigate the genetic diversity of M. catarrhalis isolates
recovered from a set of 91 Moraxella catarrhalis isolates, originating from otitis prone and
non-prone children. Further, polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis was used to investigate the presence of intra-
genomic variation in the ubiquitous surface proteins of the uspA1 and uspA2 genes (the
UspA1 and UspA2 proteins being potential vaccine candidates). Genotyping results
indicated that no particular M. catarrhalis genotype was associated with either the otitis
prone or non-prone children, and that a genetically diverse range of isolates was
present. Nineteen pairs of PFGE identical isolates were found within the 91 isolates,
with PCR-RFLP analysis showing that 1 of these 19 pairs of isolates exhibited both
uspA1 and uspA2 intra-genomic variation, whilst another pair exhibited uspA2 intra-
genomic variation only. Sequence data obtained from these variants showed that PCR-
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RFLP pattern differences reflected actual changes in predicted amino-acid composition
and that these differences were associated with minor amino-acid changes in a 23 base
pair “NINNIY” repeat region (a conserved UspA1 and UspA2 binding site for the
neutralizing antibody mAb17C7). Sequence variation in the uspA2 5’ non-coding
“AGAT” repeat region was also observed. These results showed that intra-genomic
variation of an important epitope of both the uspA1 and uspA2 genes occurs, and
indicates possible phase variation in the number of “AGAT” repeats in the uspA2 gene.
These findings may have implications for any future M. catarrhalis vaccines comprising
UspA1 and UspA2 components. Indeed, one recent publication has indicated that the
UspA1 and UspA2 proteins are unlikely to be good vaccine candidates, as distinct
populations of M. catarrhalis with a reduced or complete absence of UpsA1 and UspA2
expression may be isolated (13).
Complement Resistance Phenotype of Moraxella catarrhalis
Novel genes/mechanisms associated with the expression of the complement
resistant phenotype were explored in the following four chapters. In Chapter 7,
research was undertaken into a novel outer membrane protein (OMP J) of M. catarrhalis
that exists in two major forms (of approximately 19kDa and 16kDa molecular weight),
with each form being linked to either the complement resistant or complement
sensitive phenotype. Moreover, this newly described protein was present in 100% of
bacterial isolates tested and appeared to play a role in pulmonary clearance (as
determined using an ompJ2 gene knockout in a mouse model of infection). Subsequent
research undertaken in Chapter 8, showed that OMP J is immunogenic and that total
serum anti-OMP J immunoglobulin G (IgG) increases with age. However, there was no
significant difference in anti-OMP J IgG when the acute and convalescent serum of
children suffering from acute otitis media (AOM) disease was investigated. Passive
immunization studies did however indicate that anti-OMP J antibodies might help
facilitate the clearance of M. catarrhalis from the lungs during pulmonary infections.
The mannose binding lectin pathway (MBL) comprises one of the “arms” of
the complement system, a system that is involved in the innate immune response to
microbial pathogens (7). The ability of M. catarrhalis to activate (i.e. be recognized by)
the MBL system was investigated using a functional MBL assay in Chapter 9 (10).
Using this technique, it was found that M. catarrhalis is only a weak activator of the
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MBL system, a property that may in fact protect the organism against recognition and
attack by the (innate) immune system. This would in turn facilitate colonization and/or
infection by this organism.
Finally, Chapter 10 details the identification, sequencing and characterization
of a possible plasmid shuttle vector for the introduction and expression of complement
resistance associated genes and/or potential vaccine candidates in M. catarrhalis. Also,
despite the small-scale nature of this study, a range of plasmid sizes was found, and
some of these plasmids could potentially carry virulence factors, including antimicrobial
resistance cassettes and/or complement resistance-associated genes (9).
Conclusions and Future Perspectives
It is now accepted that M. catarrhalis is both a colonizer and a pathogen of man
on a world-wide scale, though colonization and/or changes in genotype do not
necessarily lead to the production of overt clinical disease, even in seriously ill children.
Further, preliminary evidence suggests that children are more likely to be colonized
with M. catarrhalis isolates that belong to distinct “clonal” lineages, whereas isolates
obtained from adults tend to be more genetically diverse.
Previous research has identified several virulence factors (adhesins, iron
scavenging proteins etc) that may be useful in promoting M. catarrhalis colonization, as
well as genes possibly involved in the onset of disease (e.g. genes facilitating
complement resistance). However, caution should be shown when statistical correlation
data is used to directly attribute virulence traits (e.g. the complement resistance
phenotype) to particular genes, as any association between a gene and virulence may
simply be a consequence of the fact that that particular gene is more frequently found
in a particularly virulent (clonal) M. catarrhalis lineage. In such cases, phenotypic studies
using isogenic knockout isolates are necessary in order to provide a definitive
association.
Currently, much research is geared towards the identification and evaluation of
potential vaccine candidates against M. catarrhalis, with several promising proteins
having been described. However, variation in the expression of putative vaccine
candidate proteins has been recently documented, and the immune response to these
proteins may be somewhat variable e.g. the decrease in anti-OMPE secretory IgA
observed over time after nasopharyngeal colonization of children (Cripps, AW et al, 5th
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Extraordinary International Symposium on Recent Advances in Otitis Media, 2005). It appears
therefore, that in the foreseeable future, antibiotic therapy rather than vaccination will
remain the preferred choice of treatment for M. catarrhalis-mediated infections.
Several advances have also been made with regard to the etiology of M.
catarrhalis-mediated disease per se, with growing evidence to suggest that biofilms play a
significant role in for example, the etiology of acute otitis media in children. This
finding has an important bearing on the detection of organisms and the use of
antibiotics in such infections, as planktonic (fixed) bacteria are extremely difficult to
culture and very resistant to antibiotic therapy (Post, JC. Otitis media with effusion as biofilm
disease. 5th Extraordinary International Symposium on Recent Advances in Otitis Media, 2005).
Further research on the concept of “bacterial plurality” and the particular role of M.
catarrhalis (in co-operation with S. pneumoniae and H. influenzae) in the formation of
biofilms is warranted.
Finally, two major questions regarding the epidemiology of M. catarrhalis-
mediated infection exist. Firstly, will the increase in smoking rates observed in “Third
World” and Asian countries lead to an increase in the significance of M. catarrhalis-
mediated infection within these countries, for example via an increase in chronic
obstructive pulmonary disease (COPD) and M. catarrhalis-mediated exacerbations
thereof. Secondly, will the introduction of vaccines against Streptococcus pneumoniae and
Haemophilus influenzae reduce the importance of these organisms in respiratory disease,
whilst at the same time leaving a biological niche open for exploitation by M. catarrhalis,
possibly increasing the significance of this organism in upper and lower respiratory tract
disease.
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NEDERLANDSE SAMENVATTING
Het bacteriële species M. catarrhalis werd vroeger als een algemeen humaan
commensaal organisme beschouwd met het vermogen tot kolonisatie van de
luchtwegen. In de afgelopen decennia is er toenemend bewijs verzameld voor de rol
van dit organisme bij luchtweginfecties van volwassenen en kinderen. Ontstekingen van
de bovenste luchtwegen (bijv. middenoorontsteking en bij- of voorhoofdsholte
ontstekingen) komen voornamelijk voor bij kinderen, terwijl ontstekingen van de
onderste luchtwegen (bijv. bronchitis, longontstekingen, strottenhoofdontsteking)
voornamelijk bij volwassenen worden geconstateerd. Af en toe wordt M. catarrhalis ook
bij niet-luchtweginfecties geïsoleerd, met name bloedbaaninfecties, hartklepinfecties,
bindvliesontsteking, hersenvliesontsteking, ooginfecties bij kinderen en
kraakbeenontstekingen. Er blijkt een opvallend verschil in dragerschap te zijn (tot 75%
in kinderen en 1 – 3% in volwassenen). Bovendien is M. catarrhalis seizoen gebonden en
wordt het meest frequent geïsoleerd in de winter en lente maanden. Verspreiding van
M. catarrhalis gebeurt via persoonlijk contact (speeksel) of via de handen enz., waarbij
kinderdagverblijven en peuterscholen als belangrijke bronnen van verspreiding van
bacteriële stammen tussen kinderen worden beschouwd. Een aantal uitbraken van
infecties binnen ziekenhuizen van M. catarrhalis  zijn ook waargenomen en gepubliceerd.
Onderzoek naar M. catarrhalis als pathogeen is gericht op verscheidene
relevante bacteriële eigenschappen, zoals genetische diversiteit, ziekte verwekkende
eigenschappen, de immuun respons tegen infecties en het zoeken naar een vaccin tegen
M. catarrhalis. Een uitgebreide beschrijving van deze relevante eigenschappen is in
Hoofdstuk 2 weergegeven.
Genetische diversiteit van Moraxella catarrhalis
 Tot nu toe zijn er veel verschillende technieken voor het bestuderen van de
diversiteit in M. catarrhalis ontwikkeld , inclusief  protein expression profiling (12), DNA-
DNA hybridisation (1, 3, 19), restriction fragment length polymorphism analysis (5, 8), single-
adapter amplified fragment length polymorphism analysis/16S rRNA sequencing (2), randomly
amplified polymorphic DNA analysis (18), en pulsed field gel electrophoresis (11, 17). Helaas
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bestaat er nog geen “gouden standaard” techniek voor het genetisch karakteriseren van
deze species.
In Hoofdstuk 3, werd pulsed field gel electrophoresis (PFGE) gebruikt en een
stammencollectie van 129 M. catarrhalis isolaten bestudeerd om te onderzoeken of
genetische veranderingen van M. catarrhalis stammen geïsoleerd binnen de
pediatrieafdelingen van een ziekenhuis had plaatsgevonden. Verder werd ook een
mogelijke relatie tussen genotype verandering en het verergeren van ziekten
onderzocht. PFGE resulteerde in 51 verschillende genotypen, waarbij 31% (22/70) van
de kinderen werden gekoloniseerd met twee bijzondere M. catarrhalis PFGE typen. Bij
het uitzetten van kolonisatie experimenten in een tijdslijn, bleek dat binnen de patiënt
het genotype van de koloniesant wisselde in de ziekenhuis omgeving, maar deze
typewisseling leidde niet tot een verergering van de bestaande ziekte of nieuwe ziekte
bij de kinderen. Deze resultaten laten zien dat M. catarrhalis “genotype wisseling” in
kinderen voorkomt, en dat de reële incidentie van M. catarrhalis kolonisatie in kinderen
grotendeels onderschat worden.
De PFGE techniek werd ook in Hoofdstuk 4 gebruikt om een mogelijke
relatie tussen het effect van vaccinatie tegen S. pneumoniae serotypen en kolonisatie met
bepaalde genotypen van M. catarrhalis te onderzoeken. In totaal zijn 41 M. catarrhalis
isolaten afkomstig van 13 met S. pneumoniae gevaccineerde kinderen en 21 M. catarrhalis
isolaten afkomstig van 6 met hepatitis A/B (controle) gevaccineerde kinderen
getypeerd. Geconcludeerd mag worden dat geen relatie bestaat tussen M. catarrhalis
genotype en S. pneumoniae vaccinatie. Vaccinatie tegen S. pneumoniae serotypen blijkt de
diversiteit van M. catarrhalis genotypen niet te beïnvloeden
In Hoofdstuk 5 werden de high throughput-amplification fragment length polymorphism
(htAFLP) techniek gebruikt om merkers voor fenotypische veranderingen, gecodeerd in
het DNA, op te sporen. Dit was vooral gericht op het zoeken naar merkers welke met
specifieke genetische groeperingen en/of complement resistente eigenschappen waren
verbonden. Ondanks de aanwezigheid van 2,273 polymorfe merkers en 40
groepsspecifieke merkers, word er geen enkele merker gevonden welke specifiek is voor
het complement fenotype. Eén-dimensionale SDS-PAGE gel electroforese toonde de
aanwezigheid van 6 eiwit expressie merkers aan, die significant bleken voor het
complement fenotype. De combinatie van deze genetische- en eiwit-specifieke merkers,
zouden de identificatie van virulente M. catarrhalis isolaten kunnen vereenvoudigen.
De variatie in 2 genen (uspA1 en uspA2), welke coderen voor verschillende
oppervlakte eiwitten van M. catarrhalis, werden in Hoofdstuk 6 onderzocht. In het
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bijzonder werden stammen afkomstig van middenoorontsteking-gevoelige en
middenoorontsteking-ongevoelige kinderen gebruikt. Resultaten laten zien dat er geen
specifiek genotype van M. catarrhalis bij een van beide groepen werd gevonden, en dat
variatie in de basepaar volgorde van de uspA1 en uspA2 genen kan ontstaan. Deze
variaties kunnen gevolgen hebben voor toekomstige vaccins.
Complement resistentie van Moraxella catarrhalis
Het complement systeem is een reeks eiwitten die aanwezig zijn in het bloed
van de mens, welke helpt bij bescherming tegen microbiële infecties. Deze eiwitten
kunnen op drie verschillende manieren geactiveerd werden. In de volgende 4
hoofdstukken zijn factoren die geassocieerd zijn met het complement resistente
fenotype van M. catarrhalis bestudeerd. In Hoofdstuk 7 werd een nieuw oppervlakte
eiwit (OMP J) beschreven dat eveneens bij complement resistentie is betrokken. Hierbij
komen 2 bepaalde vormen van dit eiwit voor en is er een significante associatie tussen
eiwitvorm en complement resistentie. Verder leidt het uitschakelen van dit eiwit tot een
toename in de overlevingskansen van M. catarrhalis bacteriën in de longen van muizen
(een model voor humane luchtweg infectie). In een vervolg onderzoek (beschreven in
Hoofdstuk 8) bleek OMP J immunogeen, waarbij een evenredig verband met een
toename van anti-OMP J immunoglobuline G (IgG) spiegels in serum en de leeftijd,
werd gevonden. Er werd geen significant verschil in anti-OMP J IgG spiegels in sera
afkomstig van kinderen met acute middenoorontsteking aangetoond. Echter, passieve
immunisatie studies laten zien dat antilichamen tegen OMP J dekolonisatie/eradicatie
van M. catarrhalis bacteriën uit de longen bevorderd.
Een specifieke wijze van complement activatie loopt via de aanwezigheid van
mannose (een suiker) op microbiële celoppervlakken. Deze suikers activeren de
mannose-bindende lectine (MBL) activeringsweg van het complement systeem. In
Hoofdstuk 9 werd een specifieke toetsingsmethode  gebruikt om het effect van M.
catarrhalis op de activering van MBL te bepalen. Uit onze resultaten blijkt dat M.
catarrhalis een zwakke activator van het complement systeem is.
Tot slot werd in Hoofdstuk 10 een onbekend DNA fragment (plasmide
pEMCJH03), dat zou kunnen functioneren als een vector voor het invoeren van
bacteriële genen binnen verschillende M. catarrhalis stammen, in kaart gebracht. Het
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plasmide zou een belangrijk hulpmiddel bij het maken van een vaccin tegen M.
catarrhalis kunnen zijn.
Conclusies en Toekomstperspectieven
Het is bekend dat M. catarrhalis een bacterie is die zich over de hele wereld heeft
verspreid. Tot nu toe heeft onderzoek diverse belangrijke eigenschappen van dit
organisme in kaart gebracht, zoals genen en eiwitten die betrokken zijn bij kolonisatie
en het ontstaan van ziekten bij de mens. Niettemin moeten mensen voorzichtig zijn
met hun conclusies wanneer er een statistische significante associatie tussen een bepaald
gen en een bepaald fenotype blijkt te zijn, want deze associatie hoeft niet te betekenen
dat het betrokken gen een reële rol speelt in het ontstaan van een bepaalde fenotype.
Het complement resistente fenotype is een goed voorbeeld daarvan, omdat dit fenotype
bij verschillende specifieke groepen van M. catarrhalis genotypen is aangetroffen. Ook
zijn vele andere genen of verschil in gen samenstelling met dezelfde groepen van
genotypen geassocieerd. De overgrote meerderheid van deze genen hebben niets met
complement resistentie te maken.
Op dit moment is veel onderzoek gericht op het determineren en evalueren
van mogelijke vaccineiwitten tegen M. catarrhalis. Onlangs is er een wisselende expressie
van sommige oppervlakte eiwitten geconstateerd met mogelijke gevolgen voor de
respons van het immuun systeem bijvoorbeeld op isolaten die potentiële vaccin eiwit
kandidaten niet tot expressie brengen. In elk geval zal antibioticumtherapie en niet
vaccinatie de voorkeur hebben in de behandeling van M. catarrhalis infecties in de nabije
toekomst.
Bovendien is er op dit moment een opmerkelijke vooruitgang geboekt in het
M. catarrhalis onderzoek, zoals de studie naar biofilms en de relatie hiervan met
betrekking tot het ontstaan van middenoorontsteking. Een biofilm is een gemeenschap
van bacteriële soorten omhuld door een complexe “suiker” laag, die zich vasthechten
aan weefsel oppervlakten. Zulke biofilms zijn slecht met antibiotica behandelbaar. Verder
onderzoek naar de relatie tussen M. catarrhalis en andere bacteriële ziekteverwekkers in
biofilms is noodzakelijk
Tot slot blijven twee grote vragen over M. catarrhalis infecties in de toekomst
open staan. Ten eerste, zou het toenemen van het aantal rokers in de “Derde Wereld”
en Aziatische landen, een toename in M. catarrhalis veroorzaakte luchtweginfecties
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betekenen? Ten tweede, zou het invoeren van vaccins tegen Streptococcus pneumoniae en
Haemophilus influenzae leiden tot een vermindering van deze bacteriën als veroorzakers
van luchtweginfecties en tegelijkertijd leiden tot een toenemende rol van M. catarrhalis
bij luchtweginfecties?
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